Person-Centered Treatment to Optimize Psychiatric Medication Adherence by Bareis, Natalie
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2017 
Person-Centered Treatment to Optimize Psychiatric Medication 
Adherence 
Natalie Bareis 
Virginia Commonwealth University 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Epidemiology Commons, Psychiatric and Mental Health Commons, and the Translational 
Medical Research Commons 
 
© The Author 
Downloaded from 
https://scholarscompass.vcu.edu/etd/4743 
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It 
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars 
Compass. For more information, please contact libcompass@vcu.edu. 
  
 
 
 
 
 
 
 
 
 
 
 
Person-Centered Treatment to Optimize Psychiatric Medication Adherence 
 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of 
Philosophy at Virginia Commonwealth University 
 
 
by 
 
Natalie Bareis 
 
BA Psychology, San Francisco State University, 2007 
MS Social Work, Columbia University School of Social Work, 2013 
 
 
 
 
Director: 
 
Briana Mezuk, PhD 
 
Associate Professor 
Division of Epidemiology, Department of Family Medicine and Population Health 
 
 
Virginia Commonwealth University 
Richmond, Virginia Commonwealth University 
May, 2017 
  
ii 
 
Acknowledgements 
The author wishes to thank Dr. Briana Mezuk for her tireless support of this project and 
encouragement through the years in this program as advisor and mentor. I also wish to thank my 
committee members, Dr. Juan Lu, Dr. Cynthia Kirkwood, Dr. Susan Kornstein and Dr. Elwin 
Wu, for their continued support in shaping this project. I would also like to thank Dr. Robert 
Perrera for sharing his expertise to further refine the design of this project. Finally, I wish to 
thank my parents for their support and encouragement throughout this process. 
  
iii 
 
Table of Contents 
 
List of Tables and Figures iv 
Chapter 1: Background 1 
 Methods 9 
 Overview of Analysis 19 
Chapter 2: Identifying Clinical Net Benefit of Psychotropic Medication Use with Latent 
Variable Techniques: Evidence from Systematic Treatment Enhancement Program for Bipolar 
Disorder (STEP-BD) 31 
 Abstract 32 
 Introduction 33 
 Methods 36 
 Results 42 
 Discussion 45 
Chapter 3: The Bi-directional Relationship between Clinical Net Benefit and Medication 
Adherence Over Time in Bipolar Disorder: A Latent Transition Analysis 58 
 Abstract 59 
 Introduction 61 
 Methods 64 
 Results 71 
 Discussion 77 
Chapter 4: The Bi-directional Relationship between Clinical Net Benefit and Medication 
Adherence Long Term in Bipolar Disorder: A Latent Transition Analysis 93 
 Abstract 94 
 Introduction 96 
 Methods 99 
 Results 105 
 Discussion 110 
Chapter 5: Afterword 125 
List of References 133 
Appendix 149 
Vita 156  
iv 
 
List of Tables and Figures 
Table 1.1. Psychological assessments either clinician- or self-administered to all participants in 
STEP-BD. Includes the number of participants that completed these assessments. 28 
Figure 1.1. Participant flow chart for STEP-BD. 29 
Figure 1.2. Conceptual diagram of Clinical Net Benefit latent construct. 30 
Table 2.1. Demographic Characteristics of the Full Sample, and by LCA Class. Includes logistic 
regression results testing association of classes with adherence. 47 
Table 2.2. Results from Exploratory Factor Analysis. Factor loadings are in order of importance. 
 49 
Supplemental Table 2.1. Fit Statistics from five and six class Latent Class Analyses. 50 
Supplemental Table 2.2. Overall five-class model from Latent Class Analysis, N=3,738. Higher 
scores indicate better outcomes. 51 
Supplemental Table 2.3. Medication Types in each Regimen by Class. 52 
Figure 2.1. Dots represent different hypothetical CNB groups and their relative coordinates of 
psychiatric symptoms, adverse medication effects, and overall functioning. 53 
Figure 2.2. Results of the Latent Class Analysis depicting the five classes of CNB. BHS, YMRS 
and MADRS are the Psychiatric Symptoms dimension. Tremor through Sex are the Adverse 
Effects dimension. QLESQ, LRIFT, GAF and Work Impairment are the Overall Functioning 
dimension. 54 
Figure 2.3. Psychotropic Regimens by Class. 55 
Supplemental Figure 2.1. Flowchart from original sample to current analytical sample. 56 
Supplemental Figure 2.2. Make up of Psychotropic Medication regimens by Class and Regimen 
Type. 57 
Table 3.1. Time 1 Demographic Characteristics of the full sample and by clinical net benefit 
class. Includes between group significant differences using ANOVA or chi-square analyses. 81 
Table 3.2. Class prevalence and prevalence of adherence at each time point, with indications of 
differences in adherence across classes at each time point from chi-square analyses. 83 
Table 3.3. Characteristics at Time 1 of individuals who remained in the trial for at least five time 
points compared with those who ever dropped out before Time 5. Includes between group 
significance using ANOVA and chi-square analyses. 84 
Table 3.4. a-d. Probabilities of transitions between latent classes of CNB for each pair of time 
points. Bold indicates highest probability of movement to subsequent class. 86 
Table 3.5. Results from logistic regression analyses with class membership, medication regimens 
and medication regimen change predicting adherence at each time point. 87 
v 
 
Table 3.6. Post-hoc analysis results: Odds of adherence predicted by medication regimens 
stratified by class for each time point. 88 
Supplemental Table 3.1. Fit statistics for 4 and 5 class LCAs and 4 and 5 class LTA. 89 
Figure 3.1. Classes of CNB over the course of the study. From left to right, Time 1 (a), 2 (b), 3 
(c), 4 (d) and 5 (e) at the bottom. 90 
Figure 3.2. Medication regimen change and the subsequent odds of changing to an increased or 
decreased CNB class at each time point. 91 
Supplemental Figure 3.1. Flowchart from original sample to current analytical sample. 92 
Table 4.1. Demographic characteristics of the sample at Time 5 and by clinical net benefit class, 
at the end of active monitoring. Includes between group differences from ANOVA and chi-
square analyses at P-values. 113 
Table 4.2. Class prevalence and prevalence of adherence at each time point, with significance of 
differences in adherence across classes at each time point. 115 
Table 4.3. Characteristics of individuals who remained in the trial for at least eight time points 
compared with those who ever dropped out after Time 5. Between group differences from 
ANOVA and chi-square analyses are indicated as P-values. 116 
Table 4.4. a-c. Probabilities of latent transitions between classes of CNB for each pair of time 
points. Bold indicates highest probabilities of transitioning. 118 
Table 4.5. Results of logistic regression analyses predicting adherence at each time point. Also 
shown is prediction of class change when medication regimens changed (either an increase or 
decrease in number of medications taken, or a change of medication). 119 
Table 4.6. Results of logistic regression predicting change to a higher or lower benefit class by 
prior time point medication regimen. 120 
Supplemental Table 4.1. Fit statistics for 4 and 5 class LCAs at each time point, and 4 and 5 class 
LTA. 121 
Supplemental Table 4.2. Families of medications making up different regimens taken by each 
class at Time 5. 122 
Figure 4.1. a-d. CNB LCAs for Time 5 (a), Time 6 (b), Time 7 (c) and Time 8 (d). 123 
Supplemental Figure 4.1. Flowchart from original sample to current analytical sample. 124 
1 
 
CHAPTER 1 
Background 
“Health is a state of complete physical, mental and social well-being and not merely the absence 
of disease or infirmity.”1 
 
As an increasing number of people are living with chronic conditions in the United 
States, advances in medical care are progressively focusing on quality of life for individuals with 
these conditions.2 For example, a diagnosis of human immunodeficiency virus (HIV) is no 
longer a death sentence, but can be managed as a chronic disease with current treatments.3 
However, a number of chronic illnesses have complex treatment regimens, and the effectiveness 
of these regimens is dependent on individuals strictly following instructions from their care 
providers (i.e., adhere). For example, HIV pharmacological treatment involves complex 
regimens of medications that need to be taken at specific times during the day, with exacting 
regularity or the infection will adapt to those treatments.3, 4 Diabetes is another chronic illness 
requiring complex routines including checking blood regularly, taking medication throughout the 
day, monitoring insulin administration, and dietary restrictions.5  
As treatment for these once acute illnesses has moved from an acute to chronic care 
model, there has been increasing attention to the potential for adverse effects associated with 
these medications. For example, early HIV treatments began to redistribute body fat (e.g. 
lipodystrophy) towards the abdomen leading to chronic cardiometabolic conditions and facial fat 
loss (e.g. lipoatrophy).6, 7 Adverse effects such as these were not only severe, but led to lower 
quality of life and poor adherence. To counter these effects, researchers developed new 
efficacious treatments with fewer of these adverse effects.8, 9 However, these newer treatments 
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have increased the cost of care for chronic conditions not only due to the expense of the new 
treatments, but also extending the lifespan of individuals receiving these treatments.10, 11  
 Included in this list of conditions that have moved from an acute care to chronic care 
model are psychiatric illnesses.12, 13 Bipolar disorders (BD) are among the more costly of these 
conditions to treat, due to inpatient care, the wide variety and complexity of psychotropic 
medication treatment, and disability.14 BD often onsets in the early 20s and is a life-long 
condition.15 Treatment for BD is generally divided into phases of acute symptom management 
and maintenance of symptom remission.16 Maintenance (i.e., chronic) treatment for BD focuses 
on maintaining symptom remission, often with the same treatments that were found to be 
effective during the acute stage. Although adverse effects of these medications are an 
acknowledged concern, the primary focus has been on treating these effects as they emerge, 
rather than to change medication regimens to avoid such adverse effects due to valid concerns 
that frequently changing medications can lead to instability of psychiatric symptoms.16   
Person-centered approaches to identify quality of life experienced by individuals treated 
for BD has seen increased importance to date as therapies have become more effective over 
longer periods of time.17 BD involves a wide range of symptoms, including depression, 
psychosis and manic symptoms.18, 19 This results in treatment with a broad range of medications 
including antidepressants, mood stabilizers, antipsychotics, and sedatives/hypnotics in addition 
to psychotherapy. This complexity makes it an ideal choice to study the quality of life and 
benefit of long-term medication treatment for serious mental illness more generally.  
 
 
 
3 
 
Diagnostic Criteria for Bipolar Disorder 
According to the American Psychiatric Association Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5),20 BD is characterized by signature episodes of mania or hypomania 
and episodes of depression often intermingled with euthymia (i.e., a stable mental state or mood 
that is neither manic nor depressive). Briefly, manic episodes involve at least one week of 
abnormally and persistently elevated, expansive or irritable mood with increased activity or 
energy most of the day, nearly every day. This episode must also be severe enough to cause 
marked impairment in social or occupational functioning, up to and including hospitalization, 
and may involve psychosis. A hypo-manic episode is similar to a manic episode, but lasts a 
shorter period of time and does not lead to marked impairment in social or occupational 
functioning, and does not include psychosis. Depressive episodes involve two weeks of 
depressed mood or loss of interest or pleasure, causing clinically significant distress to the 
individual and may impair functioning. Diagnosis of a manic episode is necessary for a diagnosis 
of bipolar I disorder, and a hypo-manic episode for bipolar II disorder, but a diagnosis of 
depression is not needed for a diagnosis of bipolar I disorder (DSM-5 diagnostic criteria in 
Appendix). 
Individuals with BD experience high levels of disability and healthcare costs.12 Onset of 
BD often presents as depression,15 often first detected in the emergency room, sometimes after a 
person harms themselves.21, 22 It is not uncommon for individuals in a manic episode with 
irritability to initially be detected by law enforcement, often by being arrested for belligerent 
behavior.23 Left untreated, individuals with BD have difficulty acquiring and maintaining 
employment,24 leading to poverty and use of Medicaid.25 As with other psychiatric illness, 
comorbidity with other psychiatric illnesses is extremely common. Individuals with BD most 
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commonly have comorbid anxiety disorders 26 or substance use disorders.27 Persons with BD 
have excess premature mortality.16, 28, 29  
 
Treatment options for BD 
Treatment for BD is life-long and centers on psychotropic medications. Treatment is 
generally divided into two main phases: acute symptom management and maintenance of 
symptom remission. The acute phase entails treatment at the first onset of symptoms. The 
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines recommend initial 
treatment for mania with the mood stabilizer lithium, which has consistently been found to be the 
most effective mood stabilizer.30 However, lithium has serious adverse effects that emerge 
during long-term use, including weight gain, polyuria (i.e., excessive urination), and 
hypothyroidism.31 If lithium adverse effects are intolerable, divalproex (an antiepileptic or mood 
stabilizer) is among the other first-line treatments during the acute phase.16 Due to the episodic 
nature of BD, achieving remission may take years, which has resulted in many individuals taking 
two or more psychotropic medications concurrently (i.e., polypharmacy), and even up to five or 
more different medications (i.e., complex polypharmacy) has been commonly identified.32 As 
symptoms subside and euthymia is maintained, the maintenance phase begins. Clinical 
guidelines recommend continuing whatever treatments were found to be effective from the acute 
phase while in maintenance. Other medications with known efficacy during the maintenance 
phase are lamotrigine (an antiepileptic or mood stabilizer),33, 34 and quetiapine (an 
antipsychotic)35 among others. If symptoms recur or new symptoms arise, adjunct medications 
can be added to treat those symptoms.16 Multiple adjunct medications are often needed to reach 
stability and eventual remission.32  
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Non-Adherence to Psychotropic Medication Treatment 
For all medical conditions, individuals who do not consistently adhere to their medication 
regimens often experience worse clinical outcomes, whether due to suboptimal management of 
the underlying condition or adverse effects from the medications themselves, BD is no 
exception. Unfortunately, adherence to medication is low in this population, ranging from 20-
70%.36, 37 Moreover, as individuals move into the maintenance phase of treatment they often 
experience increasingly severe symptoms that are more difficult to treat when they do not adhere 
to their medications.38  
Numerous studies have attempted to understand the factors contributing to non-adherence 
for individuals with BD from the perspective of the provider and the client. Health care providers 
suggest non-adherence is due to symptoms of the illness itself such as “lack of insight” about the 
condition 39, 40 or denial of the severity of the disorder.41 The complexity of medication regimens 
themselves (i.e., it is more difficult to take multiple medications concurrently) has been 
associated with non-adherence.42 However, as noted above, clinical guidelines indicate adding 
adjunct medications to treat new symptoms experienced while in the maintenance phase, which 
has the effect of increasing medication burden over time.  Providers have also indicated that 
adverse effects of the medications (i.e., weight gain, somnolence, sexual dysfunction) may lead 
to non-adherence.43, 44 Studies that examine the determinants of non-adherence by surveying 
individuals treated for BD suggest that concern about medications (i.e., “I sometimes worry 
about long-term effects of this medicine”) versus perceived necessity of taking those medications 
(i.e., “Without this medication I would be very ill”) is also associated with non-adherence.43 
Individuals who perceived their illness as severe and that medication was beneficial were more 
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likely to maintain adherence.40 Despite these studies, adherence remains suboptimal for persons 
with BD. 
 
Measuring Adherence 
Undermining common limitations to these studies of medication treatment for BD are the 
challenges stemming from (mis)measuring adherence. It is commonly understood that few 
individuals are perfectly adherent to their medication regimens, regardless of the condition under 
study.41 However, there is not a consistent definition of adherence or agreed upon gold standard 
of how to measure it.45, 46 For example, non-adherence could be defined as individuals’ 
inconsistently taking their medications (e.g., “drug holidays”), missing doses as a result of 
schedule changes (e.g., when traveling away from home), or taking too much of their 
medications purposefully (i.e., abuse). Non-adherence may be a general behavior, or be tied to 
specific medications. For example, individuals may  be non-adherent to one type of medication, 
but fully-adherent to others (i.e., antipsychotics versus antidepressants).46 In addition, although 
self-report of medication adherence is one of the most common ways to measure this behavior, 
and is encouraged due to the rapport building it instills between the practitioner and the 
individual they treat,47 it is subject to the same limitations of all self-report measures. The only 
way to ensure an individual is adherent is to visually confirm medication usage (e.g., component 
2 of the tuberculosis monitoring programs).48 Pill bottle counts, and even blood serum level 
measurements involve some error. Individuals may take a pill out of their bottle every day, but 
not consume the pill. Serum levels can indicate that a pill is being taken and that it has reached a 
therapeutic level, but for many longer-lasting medications it may not confirm if the medication is 
being taken at the frequency of time of day as prescribed.49  
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Modeling person-centered care for BD 
Person-centered care, as described by Davidson et al. (2015), is a patient-centered model 
of care in the medical domain recognizing the person and his/her active role beyond the “patient” 
status.50 Person-centered care is becoming more prominent in clinical settings as a means to 
identify and account for individual differences in responses to treatment for a multitude of 
illnesses, including BD.51 All medical interventions, even those benign as aspirin, have some risk 
of adverse effects. When prescribing medications, providers routinely weight the benefit versus 
risks of those treatments to arrive at a care plan that is net beneficial. Clinical guidelines indicate 
that three core aspects, or dimensions, should be considered when balancing these aspects for 
treating BD: psychiatric symptoms, adverse effects, and overall functioning.16 These dimensions 
are not independent of each other and work synergistically to influence clinical outcomes. 
Identifying how groups of individuals differentially experience these three dimensions, and 
whether this heterogeneity relates to adherence, can give further insight into improving treatment 
regimens for this population.   
 To conceptualize this intersection we have created a three-dimensional model of Clinical 
Net Benefit (CNB). Each dimension of CNB is an axis: (1) psychiatric symptoms; (2) adverse 
effects; and (3) overall functioning. The intent of this construct is to model individual 
heterogeneity in the experience of treatment for BD along each of these dimensions, grouping 
individuals at different coordinates as depicted in Figure 1.2. The relationship between adherence 
and CNB is also bi-directional: poor adherence may be a consequence of inability to tolerate 
medication adverse effects, for example. Alternatively, when individuals with BD are in 
maintenance and feel their condition is well-controlled (e.g., low psychiatric symptoms) they 
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may not take their medications as prescribed.39 Therefore the specific coordinates of individuals 
will differ, and those coordinates will change over time. 
 To address the complexity between CNB and medication adherence for BD, this research 
will address three core research questions: 
1. Can the conceptual model of CNB be identified in a population of individuals with BD? 
In addition, is this model externally valid in this population and does it enhance our 
understanding of the experiences these individuals have with their medical treatment? 
2. Does the association between CNB and adherence remain stable or change over time 
while individuals are being closely monitored by treating psychiatrists? In addition, do 
the medication regimens differentially affect adherence? 
3. Will the results from question 2 hold in a more naturalistic setting where individuals are 
not as closely monitored by their treating psychiatrist? That is, will the association 
between CNB, medication regimens, and adherence, remain stable or change over time 
when individuals do not meet as regularly with their psychiatrists? 
These questions are addressed using the Systematic Treatment Enhancement Program for 
Bipolar Disorder (STEP-BD), a large, stepped-care randomized clinical trial (RCT) for persons 
with BD. 
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Methods 
Sample 
Sachs, et al. (2003) and the ClinicalTrials.gov Systematic Treatment Enhancement 
Program for Bipolar Disorder (STEP-BD) website detail STEP-BD study design.52, 53 STEP-BD 
was a large (N=4,360) five-year longitudinal RCT designed to test the utility of different 
treatment modalities (i.e., psychotropic medications and psychotherapy) for individuals 
diagnosed with bipolar spectrum disorders (BD; i.e., meeting DSM-IV criteria for Bipolar I 
Disorder, Bipolar II Disorder, Bipolar Disorder Not Otherwise Specified [NOS], Cyclothymic 
Disorder, or Schizoaffective Disorder, Bipolar Subtype). The first two years involved active 
study participation where participants had regularly scheduled follow up appointments with their 
treating psychiatrist, and the last three years of participation involved a naturalistic follow-up 
with little oversight beyond usual care. Recruitment began in 1998 and the study ended in 2005. 
The goal of the study was to evaluate the efficacy and risk/benefit ratio of different study 
psychotropic medications (e.g., the mood stabilizers lithium, valproate and lamotrigine; the 
atypical antipsychotic risperidone; the oral supplement inositol [possible antidepressant 54]); and 
the antidepressants paroxetine, tranylcypromine and bupropion) and regimens (i.e., taking two or 
more different medications concurrently, or polypharmacy) as participants aimed to achieve 
successful psychiatric symptom management.  
STEP-BD was chosen for this analysis due to its wealth of information regarding 
psychotropic medication use, psychological assessments, large sample size, broad age range, 
diverse study population and length of follow up. The decision to use a RCT rather than a 
nationally-representative observational study was due in part to the fact that observational studies 
do not include all of these factors in one study. Nationally-representative samples such as the 
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National Health and Nutrition Examination Survey (NHANES) and the Medical Expenditure 
Panel Survey (MEPS) generally have detailed information on medications, large sample sizes 
and a broad range of ages.55, 56 However, like many population-based surveys, MEPS does not 
differentiate between major depressive disorder and BD,57 and these surveys only include 
psychological assessments measuring general distress (12-item short-form health survey (SF-12); 
Kessler-6 (K6); Center for Epidemiological Studies Depression Scale (CES-D)) 16, 58-60 or that 
are not BD specific. Also, longitudinal data is necessary to examine the bi-directional 
relationship between CNB and adherence. Moreover, there are numerous strengths to using a 
RCT as opposed to an observational study for these research questions. Finally, the STEP-BD 
trial had a public-health focused design to simulate the real-world experiences of individuals 
being treated for BD, unique for an RCT.52  
 
Inclusion Criteria 
In keeping with the “real world” perspective of STEP-BD, multiple locations and types of 
outpatient practices were selected as treatment centers for participation in the study across the 
United States. These treatment centers had to be actively treating at least 100 individuals with 
BD. They included university hospitals and medical centers (Stanford University School of 
Medicine; University of Colorado, Colorado Psychiatric Health Clinical Investigation Center; 
University of Massachusetts Medical Center; University of Oklahoma Health Sciences Center; 
University of Pennsylvania Medical Center; Baylor College of Medicine; University of Texas 
Health Science Center at San Antonio), a general hospital (Massachusetts General Hospital), a 
Veteran’s Affairs hospital (Portland Veteran’s Administration Medical Center), and two 
universities (Case Western Reserve University; University of Pittsburgh). 
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In addition, in order for treating psychiatrists or other clinical interviewers to participate 
in the study, they underwent an accredited continuing medical education program to learn Model 
Practice Procedures for routine care of individuals with BD. The main evaluation tools utilized in 
this training were the Affective Disorders Evaluation (ADE)61 and the Clinical Monitoring Form 
(CMF).62 Once psychiatrists or other clinical interviewers could demonstrate proficiency using 
these tools, they were deemed STEP-BD certified. 
Individuals were eligible to participate in the study if they were 15 years of age or older, 
could meet with their clinical specialist as scheduled and could complete all study registration 
forms within three months of registration. Written assent was given by those aged 15 to 17 years, 
with informed consent given by their legal guardians. Those aged 18 years and older gave their 
informed consent to participate. Individuals had to meet the criteria for BD to participate in the 
study, and all diagnostically eligible individuals were offered STEP-BD enrollment. These 
diagnoses were determined after administration of the ADE given by a STEP-BD certified 
psychiatrist and the Mini-International Neuropsychiatric Interview administered by a second 
certified clinical interviewer (i.e., psychiatrist, psychologist, social worker or psychiatric nurse). 
Once consensus was achieved between these two interviewers, the final diagnosis would be 
determined. Exclusion criteria for this study included an unwillingness or inability to adhere to 
basic study requirements (i.e., completing rating forms or attending scheduled evaluations), and 
lacking competence to give informed consent in the opinion of the study investigator. No healthy 
volunteers were included in the study. 
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STEP-BD Study Design: Standard Care Pathway and Randomized Care Pathways 
STEP-BD had two overall treatment pathways: the Standard Care Pathway (SCP) and the 
Randomized Care Pathways (RCPs). Upon entrance to the study, individuals were assigned to 
the SCP with individuals aged between 15 and 17 years limited to participation in the SCP, but 
those aged 18 and over could participate in either pathway. In the SCP individuals could retain 
their existing psychiatrists, if they were STEP-BD certified, and could remain on their existing 
medications and regimens, in essence treatment as usual. If a certain medication was not found to 
be efficacious, the participant’s treating psychiatrist would make the determination as to whether 
and what medication changes to make. While individuals participated in STEP-BD, they were 
also given a battery of clinician- and self-administered psychological assessments to identify 
symptoms of depression and mania, detect comorbid diagnoses, adverse effects experienced by 
participates while taking their medications, quality of life, and social and occupational 
functioning at multiple time points during study participation (Table 1.1.). Clinicians also 
determined participants’ adherence at multiple time points. 
There were three RCPs in which some medications and regimen combinations were 
randomized and placebo controlled. A participant could enter a RCP if they met criteria for that 
pathway, and were blinded to the treatments if that was the protocol for that pathway.  
Acute Depression Pathway: This pathway could be entered by individuals who met 
criteria for current major depressive episode, who were currently taking or agreed to begin taking 
a mood stabilizer, and agreed to taper off non-study antidepressants. This pathway was double-
blinded for up to 24 weeks and included two random assignments: (1) a mood stabilizer plus a 
placebo versus a mood stabilizer plus paroxetine and (2) a mood stabilizer plus a placebo versus 
a mood stabilizer plus bupropion. 
13 
 
Refractory Depression Pathway: This treatment resistant pathway, was open (non-
blinded) for up to 24 weeks. Individuals could enter this pathway if they failed to respond to 
treatment in the first two weeks while in the Acute Depression Pathway. Alternatively, they 
could enter this pathway if they failed to respond to two trials of antidepressants during their 
current depressive episode. They also needed to meet criteria for a major depressive episode for 
eight weeks before they entered the STEP-BD study. To begin this RCP, they needed to be 
currently taking or agree to begin a mood stabilizer. The three assignments were: (1) inositol 
versus risperidone; (2) risperidone versus lamotrigine; and (3) lamotrigine versus inositol. 
Relapse Prevention Pathway: This pathway was double-blinded for up to two years. An 
individual could enter this RCP if they had a manic, mixed or hypomanic episode while taking 
lithium or valproate. They also had to have normal levels of thyroid stimulating hormone and 
creatinine. The assignment for this pathway was one mood stabilizer plus a placebo versus 
divalproex plus lithium. 
As a stepped-treatment trial, treating psychiatrists’ could discontinue participants’ 
ineffective treatments and either advance to the next level of randomized treatments until they 
achieved effective symptom management, or could prescribe a different medication in the SCP. 
Additionally, participants could elect to return to the SCP at any time during their participation in 
the RCPs.  
 
Strengths and limitations of STEP-BD 
 The strengths of STEP-BD include the large number of psychological assessments 
administered at multiple time points, explicit details of psychotropic medication use identifying 
up to 12 distinct medications an individual could be taking, their dosages and missed doses, the 
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large sample size for a clinical trial, and length of follow up that included both an active 
participation phase and a naturalistic follow-up. The rigorous design of an RCT is the gold 
standard of study design, and the fact that a treatment as usual arm was also included added the 
complexity we see in an observational setting.52 
 Limitations of STEP-BD included missing data on many psychological measures 
(Chapter 1, Table 1.1.), which limited the number of measures used in the subsequent analyses. 
In addition, participants’ perceptions of their care or medications, including believes about the 
necessity of taking medications to maintain remission (i.e., scales like the Beliefs about 
Medicines Questionnaire), were not measured.63 This limited our analysis to inference on CNB 
to clinical experience, without the added knowledge of participants’ opinions and perceptions of 
benefit. Medication usage was determined via clinical interviews with the treating psychiatrist, 
which is the best-practice for large and complex trials,47 but was not confirmed by pill counts or 
blood serum levels. Finally, although STEP-BD was designed to have a diverse population of 
individuals with bipolar spectrum disorders from multiple locations across the United States, the 
sample was not nationally representative of persons with BD.  
 
Statement Regarding Human Subjects Research 
This dissertation used data from the previously collected, de-identified, limited access 
clinical trial STEP-BD. No original data was collected as part of this research. This data was 
included in the National Institute of Mental Health Data Repositories, which were accessed after 
completion of a Data Use Agreement. On June 30, 2015, the VCU Office of Research found that 
the proposed study qualified for HHS Exemption 45 CFR 46.101(b)(4) (Research involving the 
collection or study of existing data, documents, records, pathological specimens, or diagnostic 
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specimens, if these sources are publicly available or if the information is recorded by the 
investigator in such a manner that subjects cannot be identified, directly or through identifiers 
linked to the subjects) for Human Subjects Research. 
 
Measures: The Clinical Monitoring Form  
The CMF is a clinician administered assessment used at each study visit. It was designed 
as a substitute for traditional narrative clinical follow-up notes and consisted of nine sections 
including current mood modules, functional assessments and an overall clinical status.  
 
Psychiatric Symptoms 
 Beck Hopelessness Scale: The self-report 20-item BHS assesses an individual’s negative 
expectancies of the future. Each item is scored as true or false, with scores ranging from 0=none 
to 20=severe; higher scores indicating higher levels of hopelessness. Internal consistency of total 
BHS scores was found to be 0.93 by Beck, et al., (1974) with an inpatient sample of individuals 
who made recent suicide attempts.64 Later studies found the reliability to be 0.86 and 0.83 in 
psychiatric samples,65 and 0.92 in clinical populations.66, 67 Validity of the scale was based on a 
comparison between clinician ratings of hopelessness and the scale scores in both a general 
practice outpatient sample, validity of 0.74, and a psychiatric inpatient sample hospitalized for a 
recent suicide attempt, validity of 0.62.64 
 Young Mania Rating Scale: The clinician-administered 11-item YMRS assesses the 
severity of mania an individual is experiencing. Items 1, 2, 3, 4, 7, 10, and 11 are on a Likert 
scale from 0=absent to 4=severe. Items 5, 6, 8, and 9 are given extra weight as they are more 
difficult to gauge in severely impaired individuals, with a Likert scale of 0=absent to 8=severe. 
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Scores range from 0=absent to 60=severe, with higher scores indicating greater severity of mania 
symptoms. When examining an inpatient sample of manic individuals, the interrater reliability of 
the scale was 0.93 when compared between two physicians administering the scale 
independently. The concurrent validity when comparing the YMRS to other mania rating scales 
(Petterson Scale and Beigel Scale)68, 69was between 0.71 and 0.89.70 
 Montgomery-Asberg Depression Rating Scale: The clinician administered 10-item 
MADRS assesses the severity of depression with particular sensitivity to psychotropic 
medication treatment response. It is scored on a Likert scale from 0=no symptoms to 6=severe 
symptoms, and scores range from 0=absent to 50=severe, with higher scores indicating greater 
severity of the illness. Testing of the reliability and validity of the scale was conducted with a 
sample including both Swedish and English individuals with a primary depressive illness. 
Reliability between the raters ranged from 0.89 to 0.97. Validity of the scale was compared with 
a clinician’s global judgement of an individual’s response to treatment and other scales that also 
measure depression severity. MADRS had the highest correlation with the clinician’s judgement 
at 0.70.71 
Psychiatric Comorbidities 
Diagnoses of comorbid psychiatric and substance use conditions were obtained from the 
CMF. These included current alcohol abuse (yes or no), current substance abuse or dependence 
(yes or no), current panic disorder (yes or no), and current binge purge (yes or no) disorders in 
addition to the licit substance use current caffeine cups per day (continuous) and current nicotine 
packs per day (continuous).62 
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Measures: Adverse effects  
Adverse effects from medications were obtained from the CMF. Nine adverse effects 
were assessed, each rated on a 4-point Likert Scale ranging from 0=none to 4=severe. The 
adverse effects collected on the CMF were:  tremor, dry mouth, sedation, constipation, diarrhea, 
headache, poor memory, sexual dysfunction, and increase appetite. 
 
Measures: Overall Functioning  
 Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ): The 16-item QLESQ 
is completed by the participant and assesses the degree of enjoyment and satisfaction 
experienced in various areas of daily functioning. Example items include: “Taking everything 
into consideration, during the past week how satisfied have you been with your physical health?” 
Items are scored on a Likert scale from 1=very poor to 5=very good, with the first 14 items 
summed for a raw score and items 15 and 16 as stand-alone scores. Scores range from 14 to 70 
with higher scores indicating higher satisfaction. In populations with psychiatric illnesses, test-
retest reliability ranges from 0.63 to 0.89. Internal consistency ranged from 0.90 to 0.96.72 
 LIFE Range of Impaired Functioning Tool (LRIFT): The LRIFT is a tool that was 
originally administered during the Longitudinal Interval Follow-up Evaluation (LIFE) study.73 
The LIFE assessed the longitudinal course of psychiatric disorders determining time to recovery, 
length of wellness intervals and time to relapse.73 Examples of items from the LRIFT include:  
“Which of the following categories best characterizes the degree to which the patient's current 
(past week) work activities have been impaired as a result of psychopathology?” Item responses 
are on a Likert scale ranging from 1=no impairment to 5=severe impairment. In addition, four 
summary scores (work, interpersonal relations, satisfaction, and recreation) are determined: (1) 
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Work score is the sum of items 1 – 3; (2) Interpersonal relations score is the sum of items 4 – 6; 
(3) Satisfaction is the score from item 7; and Recreation is the score from item 8. These four 
scores are summed for a total score ranging from 4-20 with higher scores indicating increased 
impairment.74 The validity of the LRIFT was determined in a sample of individuals with mood 
disorders. Concurrent validity of the LRIFT compared to the Clinical Global Measures Scale, 
another measure of functioning (GAS)75 was 0.56. Reliability across the two-year study period 
ranged from 0.81 at six months to 0.83 at 24 months.74 
Work Impact Form: The WIF uses a portion of the World Health Organization Disability 
Assessment Schedule, or WHODAS-2.76 The portion utilized in STEP-BD included three 
questions regarding levels of ability to work or carry out participants’ normal activities over the 
past 30 days. For each question, there was a subset of three questions asking participants whether 
they were due to mental health or substance use. Scores for the three main questions were counts 
of the how many days in the past 30 days they experienced difficulties, and were categorized as 
0=0 days, 1=1 day, and 2=greater than 1 day. The three sub-questions were binary scores of yes 
or no.  Garin, et al., (2010) tested the validity of the full WHODAS-2 (36 items) with a sample of 
individuals with different chronic illnesses including individuals with BD.77 When compared 
with scores on the YMRS and the Hamilton Depression Rating Scale,78 the Cronbach’s 
alpha=0.88 and the Intra-class Correlation Coefficient=0.612 for individuals with BD. 
 Global Assessment of Functioning (GAF): The GAF score came from the CMF. The GAF 
is an overall assessment of psychiatric disturbance and evaluates the psychological, social and 
occupational functioning of an individual. It ranges from 1 to 100, with higher scores indicating 
higher functioning.79 In a sample of individuals with three consecutive admissions to a 
psychiatric hospital and with diagnoses of schizophrenia, schizophreniform or schizoaffective 
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disorders, the reliability of the GAF ranged from 0.89 to 0.95 over 3 time points when 
administered by two independent raters. The validity of the score when compared with the Scale 
for the Assessment of Negative Symptoms (SANS),80 Scale for the Assessment of Positive 
Symptoms (SAPS)81 and Social Behavior Schedule (SBS) 82 ranged from 0.37 to 0.77 over three 
time points.79  
 
Primary outcome: Medication Adherence assessed using the CMF 
In the CMF the treating psychiatrist indicated both the names of the medications and 
prescribed dosages, and dosages missed in the past seven days, as well as an indication of 
significant noncompliance (yes vs. no) with a space for a description of the noncompliance if 
yes. If an individual missed less than 25% of their medication dosage according to the CMF, they 
were identified as adherent. This adherence is consistent with prior analyses using STEP-BD as 
well as other analyses of adherence.83  
 
Overview of Analysis  
Chapter 2 
 Can the conceptual model of CNB be identified in a population of individuals with BD? 
In addition, is this model externally valid in this population and does it enhance our 
understanding of the experiences these individuals have with their medical treatment? 
 
The purpose of the first paper was to create the CNB construct and determine its external 
validity using data from the baseline assessment of STEP-BD. This involved two latent variable 
methods: Exploratory Factor Analysis (EFA), and Latent Class Analysis (LCA). Latent variable 
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techniques are commonly used when identifying concepts that cannot be directly measured, or 
can only be measured with error (i.e., situations in which there is no gold standard for 
assessment).84-86 For example, there is no gold standard way to measure depression, a complex 
symptom cluster of low mood and disturbances in appetite, sleep, cognition, and physical 
functioning. Instead various self-report assessments are used to identify different symptoms of 
depression and the scores on these scales are summed to determine a probable case of 
depression. Another advantage of the latent variable framework is that it does not employ 
artificial cut-points of symptom counts to determine “caseness” (e.g., DSM-5 diagnosis of major 
depression requires endorsement of 5 of 9 symptom groups, one of which is low mood or 
anhedonia). Instead, latent variable techniques like EFA and LCA use the correlations between 
variables (e.g., symptoms) to empirically identify distinct subgroups in the data (e.g., high vs. 
low depressive symptoms) rather than artificial cutpoints. Unlike regression techniques that aim 
to remove collinearity, latent variable techniques identify latent constructs by the strength of the 
very correlations between items that are indicating a common construct.87  
 
Determining the indicators of CNB using Exploratory Factor Analysis 
The goal of EFA is to reduce the number of measures (e.g., psychometric measures, 
adverse effect measures, and functioning measures) to those that are most reliable, common and 
with the highest shared variance with the three dimensions of CNB. It is a data reduction 
technique used to understand the correlation between a set of observed variables that are believed 
to describe a common (unobserved) factor. EFA is often used in the creation or modification of 
scales to measure psychological constructs. This method was used to determine the indicators 
that best describe the three dimensions of the novel construct of CNB. 
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In EFA, multiple techniques can be used to determine the number of factors and 
measured indicators that comprise a latent construct. EFA empirically identifies the number of 
indicators and factors of a latent construct that provide the best fit to the data, without any pre-
specifications as is done in Confirmatory Factor Analysis.88 We conducted three EFAs, one for 
each of the dimensions of CNB using the measures listed previously to define each latent 
construct. Measures for the psychiatric symptoms dimension included not only scales of 
symptoms such as the YMRS, but also comorbidities that may be used as self-medication or 
behaviors to mitigate psychiatric symptoms such as caffeine cups per day and binge purge 
disorders.  
EFA uses statistical methods to identify and reduce the number of measured indicators to 
only those necessary for each factor of a latent construct. It does this without a priori 
assumptions of the number of factors. The resulting latent factor should explain most of the 
shared variance seen in the associations between the original measured variables, (i.e., the 
correlation among the variables).86 For example, when creating a depression scale, one wants to 
be able to use the fewest number of questions (i.e., measured variables) necessary to accurately 
capture the latent construct of “depression”. EFA has four main assumptions: (1) measurement 
error has a constant variance that is on average approximately 0; (2) there is no association 
between the factor and measurement error; (3) there are no associations between error terms; and 
(4) given the factor, observed indicators are independent of one another (i.e., there is no 
relationship between the measured indicator except through their relationship with the factor).89, 
90 EFA can incorporate dichotomous, ordinal and continuous measures in the same analysis, 
thereby decreasing error due to transformation of variables into the same format (i.e., 
transforming all measures into dichotomous variables).88 However, EFA is sensitive to missing 
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data and outliers, therefore we could only use the measures from STEP-BD with less than 10% 
missing data, and missing data was estimated using Full Information Maximum Likelihood 
Estimation (FIML).91, 92 
To determine the final number of measures and factors from an EFA, the type of rotation 
must first be determined to use in the analysis. Rotations are the ways in which to account for the 
level of correlation between the measures as identified via the correlation matrix. If the measures 
are highly correlated an oblique rotation is used, if correlation is low an orthogonal rotation is 
used. Verimax rotation identifies preliminary factor loadings, but to group factor loadings closest 
to the two extremes (1 or 0), an additional promax rotation is needed.93 This will identify simple 
structure, factor loadings exceeding absolute value of 0.50 with cross loadings of at least 0.15 
less than item’s highest factor loading among the factors.94, 95 With factor loadings closest to the 
extremes one can be more confident that each factor is distinct from the others, with very low 
correlation between the factors.88 Results from an EFA indicate the eigenvalues for the number 
of factors up to the highest number of measures used in the analysis (if 15 measures were 
initially included, there will be 15 eigenvalues). An eigenvalue of one indicates the number of 
factors to include in the final EFA, which can also be visualized with a scree plot.96  
 
Identifying distinct subgroups based on CNB using Latent Class Analysis 
LCA is a method used to identify distinct unobserved (latent) subgroups (called classes) 
within a given population based on the correlations between a set of observed variables. LCA has 
three elements: measurement, characteristics, and grouping. First, as a measurement approach it 
evaluates whether an unobserved latent binary variable exists (i.e., do the measured indicators 
represent a common construct). Then LCA is used to determine the number of classes (i.e., 
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subgroups) of the latent variable that exist in the sample. Finally, LCA is used to assign 
participants to a particular class of the latent variable from their posterior probabilities of 
symptom endorsement.97 For example, with LCA one can assess whether a latent binary variable 
of depression exists, and then can identify different classes within that latent variable, such as 
low, medium and high levels of depression. Participants can then be assigned as belonging to the 
different classes of depression (i.e., low, medium and high). LCA has two main assumptions: (1) 
exhaustiveness is the assumption that every set of responses to measured indicators is associated 
with membership in that particular class, thus participants are provisionally assigned to a 
particular class based on their responses to the measured indicators; and (2) local independence 
assumes that members of a particular class will have independent responses from those of other 
members of the same class.98 Typically, the latent class is a binary measure, therefore ordinal, 
continuous and categorical variables must be transformed into binary variables.99 
LCA was chosen for this analysis, rather than other methods of clustering individuals into 
groups, due to the empirical nature of the analysis. LCA uses a statistical model to derive the 
groups of individuals based on their responses to measured indicators 84 rather than a more 
arbitrary method of class identification based on apparent groupings such as is used in Cluster 
Analysis.93 The measures identified in the EFA that defined each dimension of CNB were then 
included as measures of the CNB in the LCA. The scores on each measure of each dimension 
defined each class. For example, individuals would be identified by their degree of psychiatric 
symptoms (high or moderate), adverse effects (low or high) and overall functioning (moderate or 
low). Using these degrees, the classes would be identified by their overall degree of the three 
(i.e., individuals with low psychiatric symptoms, low adverse effects, and high overall 
functioning would be identified as the High CNB Class). 
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 To determine the number of classes that best fits the sample, the following measures are 
used: Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), Sample-Size 
Adjusted BIC (BICN), Bootstrapped Likelihood Ratio Test (BLRT) and Entropy.
100 For each of 
these indices smaller values, and Entropy values closest to 1, indicate better relative fit.99 With 
large sample sizes large numbers of classes may be indicated, therefore measures of model fit, 
prevalence of class membership and model interpretability are all used to determine the final 
number of classes.101 
 
Chapter 3 
Does the association between CNB and adherence remain stable or change over time 
while individuals are being closely monitored by treating psychiatrists? In addition, do the 
medication regimens differentially affect adherence? 
 
After determining the classes of CNB in STEP-BD, we wanted to test whether these 
classes changed over time and whether individuals moved between classes. In addition we 
wanted to know whether these changes affected adherence. We conducted this analysis using 
data from the active participation phase of STEP-BD, approximately two years. Two main 
methods can be used to analyze change over time of latent classes. The Repeated Measures 
Latent Class Analysis identifies the arch of change in all time points simultaneously, but does not 
give the detail regarding incidence of change between time points. We not only wanted to 
determine class membership at each time point, but also the probability of participants changing 
class membership (i.e., transitioning) at each consecutive time point. Therefore we chose to 
conduct a Latent Transition Analysis.99, 102  
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Examining the short-term relationship between CNB and Adherence using Latent Transition 
Analysis 
LTA is able to determine the probability of an individual in a specific latent class at one 
time point transitioning to the same or different class at a subsequent time point. These 
probabilities are determined by a multinomial regression of the classes at the subsequent time 
point on the classes at the previous time point (i.e., classes at time 3 regressed onto classes at 
time 2). This entails two models, a measurement model to identify the latent classes at each time 
point, (i.e., an LCA), and a structural model showing how the latent classes related to each 
other.102 The first step in conducting the LTA is to determine the best fitting number of latent 
classes at each time point using AIC, BIC, BICN, BLRT and Entropy as is done in LCA. 
However, when running the LTA, probabilities of movement between classes is also adjusted 
for, which cannot be accounted for with an LCA at each time point. This may lead to slightly 
different numbers of classes and class memberships. Thus, after determining the best fitting 
number of classes from the individual LCAs, an initial LTA should be analyzed to determine the 
number of best fitting classes when all time points are in the model.102 Fit indices for the LTA 
using AIC, BIC, and BICN can confirm if the number of LCA classes are the best fit for the LTA 
classes. For example, if the analysis using LTA will include five time points, an LCA for each 
time point should be conducted to determine the number of classes that best fit the data. If four 
and five classes fit the data for each time point, then in the LTA the fit of four classes and five 
classes should be tested to determine the number of classes that best fit the data using LTA. 
Once the best fitting classes are determined for the LTA, the actual LTA can be 
conducted. We wanted to determine if the classes themselves changed over time (i.e., values for 
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the MADRS in time two differed from time one) as well as whether participants changed classes 
at each subsequent time point. Therefore we did not hold the classes invariant across time.99, 102 
In addition, a large number of random starts is preferred to ensure the validity of the LTA results. 
However, because we were comparing multiple latent variables, we reduced the number of 
random starts as is indicated in the literature.102  
 
Chapter 4 
 Will the results from question 2 hold in a more naturalistic setting where individuals are 
not as closely monitored by their treating psychiatrist? That is, will the association between 
CNB, medication regimens, and adherence, remain stable or change over time when individuals 
do not meet as regularly with their psychiatrists? 
 
After completing the short term analysis of change in classes and CNB over the 
approximately two years of active study participation, we wanted to determine whether these 
CNB classes, changes in classes over time, and adherence held during the naturalistic follow-up 
in STEP-BD. The final three years of STEP-BD were designed to approximate the treatment 
environment in the general population, where individuals have fewer appointments with their 
treating psychiatrist leading to much less monitoring.52 The results from the LTA in Paper 2 may 
not be fully capturing adherence and CNB in a real world setting. We wanted to determine if less 
monitoring would differentially affect both CNB class membership, changes in benefit and 
subsequent adherence.  
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Examining the long-term relationship between CNB and Adherence using Latent Transition 
Analysis 
We conducted this analysis from the last time point in paper 2, time 5, until time 8, which 
was approximately the end of the three-year naturalistic follow-up. Few individuals completed 
the full five years of STEP-BD. Only approximately 200 individuals completed exit interviews, 
which is at the extreme low end of sample size with enough power to adequately complete latent 
variable modeling. Therefore, we conduct analyses using data through time 8, which gave us a 
sample size of approximately 500, considered a “very good” level of power.103  
Our analysis used the same methods as in Paper 2. We first conducted LCAs for each 
time point to determine the number of classes that best fit the data for those time points using 
AIC, BIC, BICN, BLRT and Entropy. We kept the number of classes the same across time points 
to more easily identify changes in values of the measures making up the classes of CNB and to 
identifying how class membership changed over time. Once the number of classes that best fit 
the data were determined, we conducted an LTA to confirm the fit of the number of classes using 
AIC, BIC and BICN. Finally, we conducted the LTA for time 5 – 8 to determine transition 
between classes from the previous to each subsequent time point. 
The characteristics of members of each class, including medication regimens they took, 
adherence to their regimens, and membership in SCP or RCPs were determined and compared to 
individuals who did not complete the study.  
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Table 1.1. Psychological assessments either clinician- or self-administered to all participants in 
STEP-BD. Includes the number of participants that completed these assessments. 
Clinician-Administereda Final Sample Size 
  Affective Disorders Evaluation 4107 
  Clinical Monitoring Form 3730 
  Care Utilization Form 3908 
  Demographic Form 3867 
  Family Contacts 3098 
  Montgomery-Asberg Depression Rating Scale 3931 
  Hospitalization Form 3073 
  Range of Impaired Functioning Tool 3904 
  Mini International Neuropsychiatric Interview  3790 
  UCLA Social Attainment Scale 381 
  Work Impact Form 3899 
  Young Mania Rating Scale 3927 
Participant Self-Administered  
  Beck Depression Inventory Version II 300 
  Edinbergh Handedness Inventory 2977 
  Family History 2860 
  Medication History 2963 
  NEO Five Factor Inventory 2338 
  Attributional Style Scale 265 
  Beck Hopelessness Scale 3179 
  Care Satisfaction Questionnaire 3377 
  Dysfunctional Attitudes Scale 285 
  Helping Alliance Questionnaire 2595 
  Interpersonal Support Evaluation List 283 
  Life Experience Survey 3118 
  Perceived Criticism Scale 1225 
  Personality Diagnostic Questionnaire – Version 4 2897 
  Quality of Life Enjoyment and Satisfaction (Short Form) 3371 
  Religiosity 2574 
  SF-36 Health Survey 2920 
  Social Rhythm Metric “Short Form” 31 
a. Includes treating psychiatrist, clinical specialist, or other certified rater 
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Figure 1.1. Participant flow chart for STEP-BD. 
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Figure 1.2. Conceptual diagram of Clinical Net Benefit latent construct.  
 
Caption: Dots represent different hypothetical CNB groups and their relative coordinates of psychiatric symptoms, 
adverse medication effects, and overall functioning. 
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CHAPTER 2 
Identifying Clinical Net Benefit of Psychotropic Medication Use with Latent Variable 
Techniques: Evidence from Systematic Treatment Enhancement Program for Bipolar 
Disorder (STEP-BD) 
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ABSTRACT 
Objectives: Adherence to psychotropic medication is poor among individuals with bipolar 
disorder (BD). Multiple factors influence the clinical net benefit (CNB) experienced from 
treatment, however existing models may fail to capture the complex intersection of psychiatric 
symptoms, adverse effects, and functioning. This study empirically quantified a novel construct 
of CNB and characterized its relationship with polypharmacy and medication adherence. 
Methods: Data come from baseline assessments of individuals aged 18+ from the Systematic 
Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Latent class analysis 
identified distinct groups based on the intersection of the three factors of CNB: psychiatric 
symptoms (i.e., decrease in episodes), adverse effects (e.g., sedation), and functioning (i.e., 
employment, quality of life). Adherence was defined as taking 75% or more of medications as 
prescribed. Polypharmacy was categorized as number of medications taken concurrently. 
Associations between CNB and adherence were tested using multiple logistic regression 
adjusting for sociodemographic characteristics. 
Results: Five classes of CNB were identified: High (24%), Moderately high (26%), Moderate 
(12%), Moderately low (27%) and Low (12%). Adherence did not differ between classes (71% 
to 74%, χ2=1.34, p=0.854). Medication regimens differed by class: 57% of the High CNB were 
taking two or fewer medications; 49% of the Low CNB were taking four or more medications. 
Conclusions: CNB is substantially heterogeneous in individuals treated for BD. Despite this 
variation, and differences in polypharmacy regimens, adherence is similar across classes of 
CNB. Understanding why individuals adhere to their regimens, despite suboptimal CNB, may 
provide novel insights into important aspects influencing adherence.  
Keywords: Adverse Effects, Medication Adherence, Polypharmacy, Bipolar Disorder  
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INTRODUCTION 
Bipolar disorder (BD) is among the leading causes of disability-adjusted life-years lost 
worldwide.13 Effective treatment with psychotropic medication, often in combination with 
psychotherapy, can help individuals with BD manage their illness.16, 104 
 Despite advances in pharmacotherapy, adherence to medication among individuals with 
BD has not markedly improved since the 1950’s when medications with serious adverse effects 
were the primary treatment modalities.43 Approximately 20-60% of individuals with BD will be 
non-adherent to their medication at some point in their treatment;105 medication non-adherence 
contributes to elevated relapse, suicidal behavior and greater healthcare costs.106, 107 Poor 
adherence is thought to stem from multiple sources, including effects of the illness itself (e.g., 
“lack of insight” about the condition),39, 40 adverse effects of medications (e.g., heart disease, 
somnolence),43, 44, 108 and complexity of medication regimens (e.g., multiple pills taken multiple 
times per day).39, 42  
When considering prescribing medications, practitioners routinely weigh the clinical net 
benefit (CNB) of each treatment, seeking a positive balance between expected benefits and risk 
of adverse effects.16 However, existing notions of CNB are limited in two important ways. First, 
although long-term treatment guidelines identify the importance of preventing relapse and 
promoting quality of life and functioning,104 most approaches are unidimensional (i.e., reducing 
the benefit-risk ratio to a single quantity like Number Needed to Treat).109 This does not 
appropriately capture the complexity of what CNB means for the patient; from the patient’s 
perspective, CNB of medications can be conceptualized as the complex intersection between 
psychiatric symptom reduction, medication adverse effects, and overall functioning.  
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Second, there has been only limited discussion of how CNB relates to medication 
adherence for individuals with BD, with focus instead on psychoeducation promoting adherence 
42 and the individual’s perception of their providers’ confidence in the medication regimen.110 A 
handful of studies explored how perspectives of individuals with BD relate to medication 
adherence. Using the Beliefs about Medication Questionnaire 63 Clatworthy, et al. (2009) found 
that perceptions of higher concern and lower necessity regarding medication were associated 
with lower adherence.43 Using components of the Rating of Medication Influences Scale 
(ROMI),111 Adams and Scott (2000) found that participants’ perceived benefits-to-risks for 
medications differentiated those who were highly adherent and partially adherent.112 Other 
descriptive studies of individuals with BD have identified treatment of depression, improved 
functioning, and management of adverse effects as factors most important to CNB, but these 
studies did not examine the relationships between these factors and medication adherence.16, 113 
These reports were also limited in scope (i.e., small samples, limited to one type of medication) 
and relied on self-administered mail-in questionnaires with lower validity relative to clinical 
assessments.113-115  
The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) 
overcame many limitations of these prior studies. It was a large (N=4360), 5-year longitudinal 
randomized controlled trial (RCT) designed to test the utility of different treatment modalities 
(medications and psychotherapy) for individuals with BD. It included stepped-treatment where 
participants were allowed to discontinue ineffective treatments and advance to the next level of 
randomized treatments until they achieved effective symptom management. Participants were 
also given a battery of clinician- and self-administered psychological assessments as well as 
clinician determined medication adherence at multiple time points.52  
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The objective of this study was to use the baseline assessments of STEP-BD participants 
to identify and characterize subgroups of CNB. Due to the complex, multi-dimensional nature of 
CNB this project employed two latent variable approaches, exploratory factor analysis (EFA) 
and latent class analysis (LCA), to quantify CNB in the context of medical treatment.116 Latent 
variable modeling is ideal for quantifying a complex construct such as CNB,117, 118 and can 
effectively classify people into discrete subgroups. Classes of CNB were characterized according 
to indicators of symptom management, adverse effects, and overall functioning. Further, the 
association between these CNB classes with characteristics of medication treatment (i.e., type of 
medication, polypharmacy) and medication adherence was assessed. We hypothesized that LCA 
will identify unique classes of individuals who systematically differ in characteristics of CNB. 
We also hypothesized that these distinct classes will be differentially associated with medication 
adherence. 
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METHODS 
Sample 
All eligible participants aged 18 years and older from the STEP-BD trial were included in 
the current study, as medications prescribed in STEP-BD were only approved for this population 
when the study began.119, 120 The details of the original study design were described elsewhere.52 
Briefly, STEP-BD was a 5-year RCT of individuals treated for bipolar spectrum disorders. It was 
designed to simulate the “real world” experiences in treatment of individuals with BD. STEP-BD 
was not solely a RCT, as eligible participants could choose to enter either the Randomized Care 
Pathways (RCPs) or Standardized Care Pathway (SCP). In the RCPs, participants were randomly 
assigned to specific medications (i.e., mood stabilizers, antipsychotics, antidepressants or 
placebos) to minimize self-selection bias. In the SCP, participants maintained current treatment. 
If initial regimens were ineffective, participants moved on to subsequent medications until an 
effective regimen was reached. Participants routinely underwent a battery of clinician- and self-
administered psychological assessments, including medication adherence.  
 Although 4,360 participants enrolled in the original study, this study further excluded 321 
participants with incomplete data on the psychological assessments and physical measures with 
less than 10% missing data used in this analysis, and 301 individuals who were less than aged 18 
years. Missing data <10% was imputed using Full Information Likelihood Estimation.92 The 
final analytic sample size was 3,738 (Supplemental Figure 2.1.). 
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Outcomes 
Clinical Net Benefit 
CNB incorporates three main effects of treatment on the individual: (1) symptom 
reduction; (2) adverse effects; and (3) overall functioning. CNB can be conceptualized as a 3-
dimensional construct lying at the intersection of these axes. Individuals differentially experience 
these components of treatment, depicted as points in Figure 2.1. These different experiences, or 
coordinates, may in turn uniquely relate to medication adherence. To conceptually define and 
quantitatively measure these three dimensions of CNB, we used the baseline scores of the 
following variables. Three EFAs empirically reduced measures to only those necessary for the 
three dimensions of CNB. LCA then grouped participants into distinct subgroups of CNB. 
 Psychiatric Symptoms 
 Nine symptom scales and psychiatric diagnoses were explored as potential indicators of 
this component of CNB at baseline.16 All symptom indicators were reverse coded such that 
higher scores indicated lower symptomology. The treating psychiatrist-administered Clinical 
Monitoring Form (CMF),62 indicated binary (yes/no) comorbid DSM-IV diagnoses of alcohol 
abuse, substance abuse/dependence, binge/purge, and panic disorder; the number of caffeine 
cups per day (mean: 1.83, SD: 2.35) and number of cigarettes per day (mean: 6.04, SD: 10.96) 
were transformed into binary variables above and below the sample mean. Mania and depression 
were measured using the participant self-reported 20-item Beck Hopelessness Scale (BHS) 
(range: 0=none to 20=severe; mean: 11.49, SD: 5.75); the clinician-rated 11-item Young Mania 
Rating Scale (YMRS) (range: 0=absent to 60=severe; mean: 32.00, SD: 6.53); and the clinician-
rated 10-item Montgomery-Asberg Depression Rating Scale (MADRS) (0=absent to 50=severe; 
mean: 33.19, SD: 10.90). Externalizing symptoms (i.e., alcohol abuse, substance 
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abuse/dependence, binge/purge, caffeine cups per day, cigarettes per day)117 were combined into 
an externalizing count variable. 
 Adverse Effects 
 Ten adverse effects from the CMF were explored as potential indicators of CNB at 
baseline. Each was scored on a 4-point scale ranging from 0=none to 4=severe. All of these 
indicators were reverse coded so that higher scores indicated fewer effects. These included 
tremor (mean: 3.77, SD: 0.60); dry mouth (mean: 3.75, SD: 0.63); sedation (mean: 3.70, SD: 
0.69); constipation (mean: 3.90, SD: 0.43); diarrhea (mean: 3.88, SD: 0.45); headache (mean: 
3.78, SD: 0.60); poor memory (mean: 3.74, SD: 0.64); sexual dysfunction (mean: 3.80, SD: 
0.63); increased appetite (mean: 3.80, SD: 0.60); and extrapyramidal symptoms (mean: 3.99, SD: 
0.17).  
 Overall Functioning 
 Four scales were explored as potential indicators of CNB at baseline. All items were 
reverse-coded so higher scores indicated better functioning: (1) participant self-reported 16-item 
Quality of Life Enjoyment and Satisfaction Questionnaire (QLESQ) (mean: 42.53, SD: 10.87); 
(2) clinician-rated LIFE Range of Impaired Functioning Tool (LRIFT),74 (mean: 39.88, SD: 
6.45); (3) three indicators from the clinician-rated Work Impact Form (WIF), were combined 
creating a weighted work impairment score (totally unable to work/carry out normal activities 
score X 2; able to work/carry out normal activities but had to cut down score X 1.5; extreme 
effort to perform up to usual level of work/normal daily activities score X 1) (ranging from 0=no 
impact to 9=high impact; mean: 4.18, SD: 3.11); (4) the CMF Global Assessment of Functioning 
(GAF) for the past week (mean: 62.40, SD: 11.07).  
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Adherence 
 The CMF recorded milligrams missed for each medication in the past seven days at 
baseline. Adherence was defined as missing 25% or less of participants’ medication regimens in 
the past week; participants who missed more than 25% were considered non-adherent. This is 
consistent with the definitions used in STEP-BD studies.83 
Demographic Characteristics 
 Demographic characteristics at baseline included age; gender; race (White, Black, and 
Other); educational attainment (≤high school, high school diploma or GED, some college, 
Bachelor’s degree, and Graduate or professional degree); current marital status (married or living 
as though married, divorced or separated, never married, or widowed); whether participants lived 
alone; primary residence (private home, group home or something else); income (greater or less 
than $50,000); whether participants received disability insurance or welfare; and employment 
status (employed, unemployed, disabled or something else). In addition, whether individuals 
entered the SCPs or RCPs were noted. 
Medication 
Medications taken at baseline were listed by name (either generic or brand) on the CMF. 
All medications were identified and grouped into six families: (1) antidepressants, (2) mood 
stabilizers, (3) antipsychotics, (4) sedatives/hypnotics, (5) stimulants, and (6) other.121 A regimen 
count variable was created indicating whether a participant was taking one (monotherapy), two, 
three, four or five or more medications (polypharmacy).  
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Analytic Approach  
Analyses took place in two steps. First, EFAs reduced the number of measures to only 
those necessary to comprise each of the three dimensions of CNB (symptoms, adverse effects, 
and functioning). Second, LCA grouped the participants into distinct classes (subgroups) of 
CNB. We characterized and examined the correlates of those subgroups in terms of demographic 
characteristics, medication regimens and medication adherence.  
Exploratory Factor Analysis 
We conducted three EFAs, (psychiatric symptoms, adverse effects and overall 
functioning) using the previously described indicators. Using Equamax rotation,122 eigenvalues > 
one indicated the number of factors to retain. We only retained indicators meeting the definition 
of simple structure (factor loadings exceeding 0.50 and a cross loading of at least 0.15 less than 
the items’ highest factor loading).87, 88, 94-96  
Latent Class Analysis 
To improve interpretability of the classes, we dichotomized all continuous and ordinal 
indicators retained from the EFAs based on the participants’ mean scores,123, 124 with 1=above 
the mean (better outcomes). The number of distinct latent classes of CNB were determined by 
comparing model fit using the Akaike Information Criterion (AIC), Bayesian Information 
Criterion (BIC), Sample-Size Adjusted BIC (BICN), Bootstrapped Likelihood Ratio Test (BLRT) 
and Entropy; for each of these indices smaller values, and Entropy values closest to 1, indicate 
better relative fit. Measures of model fit, prevalence of class membership and model 
interpretability were all used to determine the final number of classes.97, 125 Most likely class 
membership for each participant was determined from their posterior probabilities. 
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Characterizing the latent classes of CNB 
The demographic characteristics, adherence to medication regimens, types of medication 
regimens (i.e., monotherapy versus polypharmacy) and makeup of these medication regimens 
(i.e., percent antidepressants versus mood stabilizers) of the latent classes of CNB were 
compared using ANOVA for continuous measures and Chi-square analyses for categorical 
measures.  
Descriptive statistics were calculated using SAS version 9.4 (SAS Institute Inc.). EFA 
and LCA were conducted using Mplus version 7.91  
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RESULTS 
 Table 2.1. describes the baseline characteristics of the sample. Mean age was 40 years, a 
little over half (58%) were female and 91% were non-Hispanic white. Only 1% lived in group 
homes, and most lived with at least one other person (73%). Over 15% received Social Security 
Disability Insurance. Two medications were the most common regimen, and 72% of participants 
were adherent to their medication regimen. Only 5% of the sample entered a RCP. 
Exploratory Factor Analysis 
 Table 2.2. provides factor loadings for the three EFAs. Eigenvalues for the psychiatric 
symptoms EFA indicated one factor (first factor: 1.981, and second factor: 0.950). Although the 
factor loading for YMRS was less than 0.50 (0.312), BHS and MADRS only measure depressive 
states, therefore YMRS was retained to account for mania. The final psychiatric symptoms EFA 
retained one factor with three indicators: MADRS, BHS and YMRS. The overall functioning 
EFA eigenvalues indicated a one factor model (first factor: 2.090 and second factor: 0.704), 
therefore the final overall functioning EFA retained one factor with four indicators: QLESQ, 
LRIFT, GAF and Work Impairment. Although the eigenvalues for the adverse effects EFA 
indicated a two factor model (first factor: 4.179 and second factor: 1.123), the second factor had 
only one measure. Therefore, the one factor model was retained, and the final adverse effects 
EFA included: memory difficulties, dry mouth, sexual dysfunction, headache, constipation, 
sedation, diarrhea, and tremor. 
Latent Class Analysis 
 Model fit statistics indicated that both the five and six class models had comparable fit 
(Supplementary Table 2.1.). However, the smallest class in the five class model consisted of 
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N=432 (12%) of the participants, whereas the smallest class in the six class model consisted of 
only N=259 (7%) of the participants. Thus, the five class model was chosen due to the best 
balance of interpretability and model fit. 
 Results for the five class model of CNB defined by their responses on the three 
dimensions of CNB (psychiatric symptoms, overall functioning, and adverse effects) are in 
Figure 2.2. and Supplementary Table 2.2. The five classes were: (1) high benefit (low symptoms, 
low adverse effects and high functioning; class prevalence: 24%); (2) moderately high benefit 
(moderate symptoms, low adverse effects and moderate functioning; class prevalence 26%); (3) 
moderate benefit (moderate symptoms, moderate adverse effects and moderate functioning; class 
prevalence 12%); (4) moderately low benefit (high symptoms, low adverse effects and low 
functioning; class prevalence 27%); and (5) low benefit (high symptoms, moderate adverse 
effects, and low functioning; class prevalence 12%).  
Characterizing the classes 
The results of both the ANOVA and Chi-square tests between the classes are indicated as 
P-values in Table 2.1. Classes differed in all characteristics except in terms of age (F=2.01; 
p=0.09), race (χ2=5.51, p=0.70) and primary residence (χ2=8.33, p=0.40). The high benefit class 
had the highest proportion with graduate education (N=189, 24%), employment (N=467, 57%) 
and the lowest percentage entering the RCP (N=5, 0.61%), while the low benefit class had the 
highest proportion unemployed (N=117, 28%), receiving social security disability insurance 
(N=87, 21%) and entering the RCP (N=42, 10%). 
Medication adherence did not differ across the classes (χ2=1.34, p=0.854), ranging 
between 71% and 74%. This held true after adjusting for all significantly different between class 
demographic characteristics including medication regimens (i.e., monotherapy versus taking five 
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or more medications; see bottom of Table 2.1.). However, medication regimens did differ 
between classes (χ2=167.39, p<0.001; see Figure 2.3.). In the high benefit class over 50% were 
taking two or fewer medications. In contrast, in the low benefit class almost 50% were taking 
four or more medications. Only the monotherapy regimens (i.e., proportions of antidepressants, 
mood stabilizers, etc.) differed between the classes (Supplementary Table 2.3. and 
Supplementary Figure 2.2.; χ2=39.8, p<0.001). As the number of medications increased (i.e., two 
medications to three medications) the percent mood stabilizers decreased and other medications 
taken increased in all classes (i.e., 84% to 28% and 2% to 34% respectively in the high benefit 
class). 
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DISCUSSION 
 The primary finding from this study is that the notion of CNB from medical intervention 
can be expanded beyond traditional metrics using latent variable techniques. We empirically 
identified subgroups of individuals with distinctly intersecting clinical characteristics of 
psychiatric symptoms, adverse effects and overall functioning using a novel three dimensional 
model. Supporting our hypothesis and the external validity of these classes of CNB, the five 
subgroups of high, moderately high, moderate, moderately low and low benefit also differed in 
terms of sociodemographic characteristics such as education, employment, disability status, and 
entry into the Randomized versus Standard Care Pathways in STEP-BD. 
Importantly, contrary to our hypothesis, although classes differed in the three CNB 
dimensions, they did not differ in medication adherence. Approximately 70% were adherent, 
which is typical for BD populations.42 These results suggest that factors associated with 
adherence identified by prior work (e.g., effects of the illness itself, adverse effects from 
medications, and complex regimens) are only part of the complex interplay of experiences 
individuals have of their illness and its treatment. Future work should examine whether the 
relationship between CNB and adherence changes over time. 
Strengths and Limitations 
 Strengths of this study include use of a large RCT with rigorous and extensive 
assessments. STEP-BD was a more heterogeneous sample than most RCTs in that it enrolled 
individuals with comorbidities, already taking medications, at different stages of illness, from a 
wide age range, and from the full spectrum of BD; this increases generalizability of the results. 
By using latent variable techniques we empirically identified the indicators of CNB rather than 
relying solely on theoretical conceptualizations. Finally, detailed information on medications 
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allowed us to examine components of complex medication regimens commonly used to treat 
individuals with BD and their relationship with adherence. 
 Limitations included the lack of measures of participants’ perceptions of their illness or 
of medications used to treat it, or of their individual preferences. Medication usage was not 
confirmed by pill counts or blood serum levels; however, the clinical interview used here is best-
practice for large, complex trials like STEP-BD. Missing data limited the number of measures 
used to describe the CNB construct.  
Conclusions 
Our findings support the importance of collaborative, person-centered, shared decision-
making approaches to treatment to identify targets for supporting medication adherence. Our 
results are broadly consistent with previous studies of the experience of individuals with BD that 
highlight the importance of perceived necessity of medication versus concerns about adverse 
effects; if perceptions of necessity outweigh concerns, individuals may continue taking their 
medications even if symptom management and functioning is suboptimal. This may contribute to 
the unexpected finding of high adherence across these groups that differed substantially in CNB.  
 
 
47 
 
Table 2.1. Demographic Characteristics of the Full Sample, and by LCA Class. Includes logistic regression results testing association of classes with adherence*. 
 Full Sample Class 1 Class 2 Class 3 Class 4 Class 5 P-values 
  High Benefit Moderately High 
Benefit 
Moderate Benefit Moderately Low 
Benefit 
Low Benefit  
N (%) 3738 889 (23.78) 961 (25.71) 432 (11.56) 1010 (27.02) 446 (11.93)  
Age (Mean, SD) 40.45 (12.78) 
N=3568 
41.13 (14.33) 
N=837 
39.54 (12.93) 
N=930 
41.04 (13.18) 
N=417 
40.50 (11.39) 
N=958 
40.46 (11.65) 
N=426 
0.091 
Female – no./total no. (%) 2054/3563 (57.65) 445/837 (53.17) 530/929 (57.05) 266/417 (63.79) 553/955 (57.91) 260/425 (61.18) 0.004 
Race – no./total no. (%)       0.702 
 White 2531/2789 (90.75) 565/621 (90.98) 656/724 (90.61) 281/305 (92.13) 722/798 (90.48) 307/341 (90.03)  
 Black 162/2789 (5.81) 33/621 (5.31) 45/724 (6.22) 12/305 (3.93) 53/798 (6.64) 19/341 (5.57)  
 Other 96/2789 (3.44) 23/621 (3.70) 23/724 (3.18) 12/305 (3.93) 23/798 (2.88) 15/341 (4.40)  
Education – no./total no. (%)       <0.001 
 Less than high school diploma 105/3448 (3.05) 16/800 (2.00) 29/907 (3.20) 6/401 (1.50) 44/926 (4.75) 10/414 (2.42)  
 High school diploma or GED 521/3448 (15.11) 100/800 (12.50) 127/907 (14.00) 42/401 (10.47) 168/926 (18.14) 84/414 (20.29)  
 Some college 1296/3448 (37.59) 256/800 (32.00) 335/907 (36.93) 143/401 (35.66) 390/926 (42.12) 172/414 (41.55)  
 College diploma (Bachelor’s degree) 911/3448 (26.42) 239/800 (29.88) 265/907 (29.22) 118/401 (29.43) 197/926 (21.27) 92/414 (22.22)  
 Graduate or professional degree 615/3448 (17.84) 189/800 (23.63) 151/907 (16.65) 92/401 (22.94) 127/926 (13.71) 56/414 (13.53)  
Marital Status – no./total no. (%)       <0.001 
 Married/Living as married 1300/3531 (36.82) 305/829 (36.79) 336/923 (36.40) 174/414 (42.03) 313/942 (33.23) 172/423 (40.66)  
 Divorced/Separated 888/3531 (25.15) 171/829 (20.63) 214/923 (23.19) 98/414 (23.67) 298/942 (31.63) 107/423 (25.30)  
 Never married 1285/3531 (36.39) 341/829 (41.13) 357/923 (38.68) 137/414 (33.09) 317/942 (33.65) 133/423 (31.44)  
 Widowed 58/3531 (1.64) 12/829 (1.45) 16/923 (1.73) 5/414 (1.21) 14/942 (1.49) 11/423 (2.60)  
Lives alone – no./total no. (%) 956/3526 (27.11) 232/828 (28.02) 226/922 (24.51) 113/414 (27.29) 287/940 (30.53) 98/422 (23.22) 0.015 
Primary residence – no./total no. (%)       0.402 
 Private home 3310/3459 (95.69) 767/801 (95.76) 869/910 (95.49) 375/400 (93.75) 898/932 (96.35) 401/416 (96.39)  
 Group home/assisted living facility 37/3459 (1.07) 8/801 (1.00) 9/910 (0.99) 4/400 (1.00) 11/932 (1.18) 5/416 (1.20)  
 Other 112/3459 (3.24) 26/801 (3.25) 32/910 (3.52) 21/400 (5.25) 23/932 (2.47) 10/416 (2.40)  
Income – no./total no. (%)       <0.001 
 $50,000 or less 1968/3261 (60.35) 413/760 (54.34) 505/851 (59.34) 201/382 (52.62) 603/873 (69.07) 246/395 (62.28)  
 More than $50,000 1293/3261 (39.65) 347/760 (45.66) 346/851 (40.66) 181/382 (47.38) 270/873 (30.93) 149/395 (37.72)  
Other sources of income        
 SSDI – no./total no. (%) 523/3405 (15.36) 78/786 (9.92) 119/894 (13.31) 55/395 (13.92) 184/921 (19.98) 87/409 (21.27) <0.001 
 Welfare – no./total no. (%) 65/3405 (1.91) 5/786 (0.64) 7/894 (0.78) 8/395 (2.03) 30/921 (3.26) 15/409 (3.67) <0.001 
Employment – no./total no. (%)       <0.001 
 Employed 1623/3504 (46.32) 467/818 (57.09) 432/917 (47.11) 202/414 (48.79) 372/934 (39.83) 150/421 (35.63)  
 Unemployed 816/3504 (23.29) 157/818 (19.19) 229/917 (24.97) 87/414 (21.01) 226/934 (24.20) 117/421 (27.79)  
 Disabled 629/3504 (17.95) 74/818 (9.05) 138/917 (15.05) 62/414 (14.98) 250/934 (26.77) 105/421 (24.94)  
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 Other 436/3504 (12.44) 120/818 (14.67) 118/917 (12.87) 63/414 (15.22) 86/934 (9.21) 49/421 (11.64)  
Medication Regimens – no./total no. (%)       <0.001 
 Monotherapy 620/3393 (18.27) 202/785 (25.73) 150/869 (17.26) 57/429 (13.29) 158/875 (18.06) 53/435 (12.18)  
 Two Medications 863/3393 (25.43) 244/785 (31.08) 249/869 (28.65) 85/429 (19.81) 208/875 (23.77) 77/435 (17.70)  
 Three Medications 738/3393 (21.75) 145/785 (18.47) 203/869 (23.36) 87/429 (20.28) 210/875 (24.00) 93/435 (21.38)  
 Four Medications 504/3393 (14.85) 85/785 (10.83) 130/869 (14.96) 69/429 (16.08) 145/875 (16.57) 75/435 (17.24)  
 Five or More Medications 668/3393 (19.69) 109/785 (13.89) 137/869 (15.77) 131/429 (30.54) 154/875 (17.60) 137/435 (31.49)  
Adhere – no./total no. (%) 2423/3347 (72.39) 557/769 (72.43) 626/862 (72.62) 315/424 (74.29) 620/862 (71.93) 305/430 (70.93) 0.854 
Pathway       <0.001 
 Standardized Care 3344/3537 (94.54) 816/821 (99.39) 869/918 (94.66) 416/431 (96.52) 844/926 (91.14) 399/441 (90.48)  
 Randomized Care 193/3537 (5.46) 5/821 (0.61) 49/918 (5.34) 15/431 (3.48) 82/926 (8.86) 42/441 (9.52)  
        
Predicting Adherence       
Classes (Ref=High Benefit) OR (95% CI)       
  Moderately High Benefit 0.95 (0.74-1.21)       
  Moderate Benefit 0.89 (0.65-1.20)       
  Moderately Low Benefit 1.03 (0.81-1.32)       
  Low Benefit 1.09 (0.81-1.47)       
* Adjusted for medication regimens, gender, education, marital status, lives alone, income, social security disability insurance, welfare, and employment 
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Table 2.2. Results from Exploratory Factor Analysis. Factor loadings are in order of importance. 
 
 
  
Measures Factor Loadings 
Psychiatric Symptoms  
 MADRS 0.808 
 BHS 0.652 
 Panic 0.404 
 YMRS 0.312 
 Externalizing Disorders* -0.199 
Adverse Events  
 Memory Difficulties 0.804 
 Dry Mouth 0.733 
 Sexual Dysfunction 0.678 
 Headache 0.644 
 Constipation 0.601 
 Sedation 0.600 
 Diarrhea 0.537 
 Tremor 0.535 
 Appetite Increase 0.487 
 EPS 0.230 
Functioning  
 QLESQ 0.703 
 LRIFT 0.629 
 GAF Past Week 0.557 
 Work Impact Score** 0.523 
Bold=Kept in model 
*Count that combined: Alcohol Abuse (Y/N); Current 
Substance Abuse or Dependence (Y/N); Binge Purge 
(Y/N); Caffeine Cups Per Day (cont.); Nicotine Packs 
Per Day (cont.) 
**Weighted combination: Unable to work or carry out 
normal activities; Had to cut down on what you did; 
Extreme effort to perform usual level of normal 
activities 
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Supplemental Table 2.1. Fit Statistics from five and six class Latent Class Analyses.  
Class AIC BIC BICN BLRT Entropy 
Five Classes 51734.203 52226.081 51975.057 181.755, p<0.001a 0.710 
Six Classes 51692.095 52283.594 51981.730 74.108, p<0.001b 0.687 
For each of these indices smaller values, and Entropy values closest to 1, indicate better 
relative fit. 
AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; BICN: Sample-
Size Adjusted BIC; BLRT: Bootstrapped Likelihood Ratio Test 
a BLRT for 4-class versus 5-class model 
b BLRT for 5-class versus 6-class model 
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Supplemental Table 2.2. Overall five-class model from Latent Class Analysis, N=3,738. Higher scores indicate better outcomes. 
Clinical Net Benefit 
 
Class 1 
High Benefit 
Class 2 
Moderately High Benefit 
Class 3 
Moderate Benefit 
Class 4 
Moderately Low Benefit 
Class 5 
Low Benefit 
Predicted Probabilities of Symptom Endorsement 
Psychiatric Symptoms      
 BHS 0.922 0.688 0.782 0.138 0.165 
 YMRS 0.825 0.607 0.698 0.516 0.522 
 MADRS 1.000 0.545 0.817 0.084 0.131 
Adverse Effects      
 Tremor 0.921 0.927 0.612 0.907 0.592 
 Dry Mouth 0.957 0.973 0.477 0.942 0.390 
 Sedation 0.924 0.910 0.467 0.911 0.487 
 Constipation 0.981 0.987 0.793 0.983 0.742 
 Diarrhea 0.968 0.976 0.775 0.967 0.743 
 Headache 0.955 0.958 0.635 0.943 0.477 
 Memory Difficulties 0.976 0.969 0.488 0.976 0.311 
 Sexual Dysfunction 0.982 0.976 0.690 0.969 0.577 
Overall Functioning      
 QLESQ 0.913 0.557 0.796 0.105 0.134 
 LRIFT 0.916 0.585 0.779 0.195 0.291 
 GAF Past Week 0.845 0.490 0.603 0.204 0.189 
 Work Impact Score 0.789 0.349 0.546 0.218 0.190 
BHS: Beck Hopelessness Scale; YMRS: Young Mania Rating Scale; MADRS: Montgomery-Asberg Depression Rating Scale; 
QLESQ: Quality of Life Enjoyment and Satisfaction Questionnaire; LRIFT: Life Range of Impaired Functioning; GAF: Global 
Assessment of Functioning 
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Supplemental Table 2.3. Medication Types in each Regimen by Class. 
 Antidepressant  Mood Stabilizer  Antipsychotic  Sedative/Hypnotic Stimulant  Other 
Class 1 High Benefit       
  Monotherapy (N=202)* 13 (6.44) 169 (83.66) 15 (7.43) -- -- 5 (2.48) 
  Two Medications (N=244) 93 (19.06) 255 (52.25) 72 (14.75) 17 (3.48) 2 (0.41) 49 (10.04) 
  Three Medications (N=145) 80 (18.39) 178 (40.92) 61 (14.02) 38 (8.74) 4 (0.92) 74 (17.01) 
  Four Medications (N=85) 54 (15.88) 120 (35.29) 44 (12.94) 34 (10.00) 2 (0.59) 86 (25.29) 
  Five + Medications (N=109) 85 (15.60) 155 (28.44) 54 (9.91) 57 (10.46) 8 (1.47) 186 (34.13) 
Class 2 Moderately High Benefit       
  Monotherapy (N=150) 11 (7.33) 119 (79.33) 13 (8.67) 3 (2.00) -- 4 (2.67) 
  Two Medications (N=249) 103 (20.68) 262 (52.61) 66 (13.25) 21 (4.22) 5 (1.00) 41 (8.23) 
  Three Medications (N=203) 135 (22.17) 268 (44.01) 85 (13.96) 60 (9.85) 7 (1.15) 54 (8.87 
  Four Medications (N=130) 81 (15.58) 191 (36.73) 58 (11.15) 54 (10.38) 8 (1.54) 128 (24.62) 
  Five + Medications (N=137) 100 (14.53) 221 (32.12) 82 (11.92) 86 (12.50) 8 (1.16) 191 (27.76) 
Class 3 Moderate Benefit       
  Monotherapy (N=57) 6 (10.53) 42 (73.68) 6 (10.53) -- -- 3 (5.26) 
  Two Medications (N=85) 31 (18.24) 83 (48.82) 30 (17.65) 13 (7.65) -- 13 (7.65) 
  Three Medications (N=86) 44 (17.05) 106 (41.09) 41 (15.89) 21 (8.14) 1 (0.39) 45 (17.44) 
  Four Medications (N=70) 64 (22.86) 95 (33.93) 39 (13.93) 31 (11.07) 2 (0.71) 49 (17.50) 
  Five + Medications (N=131) 106 (15.87) 195 (29.19) 78 (11.68) 61 (9.13) 3 (0.45) 225 (33.68) 
Class 4 Moderately Low Benefit       
  Monotherapy (N=158) 12 (7.59) 122 (77.22) 16 (10.13) 4 (2.53) -- 4 (2.53) 
  Two Medications (N=208) 93 (22.36) 207 (49.76) 50 (12.02) 26 (6.25) 1 (0.24) 39 (9.38) 
  Three Medications (N=210) 128 (20.32) 255 (40.48) 95 (15.08) 74 (11.75) 3 (0.48) 75 (11.90) 
  Four Medications (N=145) 107 (18.45) 212 (36.55) 69 (11.90) 92 (15.86) 7 (1.21) 93 (16.03) 
  Five + Medications (N=154) 126 (16.20) 228 (29.31) 96 (12.33) 126 (16.20) 10 (1.29) 192 (24.68) 
Class 5 Low Benefit       
  Monotherapy (N=53) 10 (18.87) 25 (47.17) 10 (18.87) 3 (5.66) -- 5 (9.43) 
  Two Medications (N=77) 28 (18.18) 69 (44.81) 19 (12.34) 13 (8.44) 1 (0.65) 24 (15.58) 
  Three Medications (N=93) 74 (26.52) 102 (36.56) 31 (11.11) 35 (12.54) -- 37 (13.26 
  Four Medications (N=75) 58 (19.33) 98 (32.67) 40 (13.33) 42 (14.00) 2 (0.67 60 (20.00) 
  Five + Medications (N=137) 142 (20.11) 187 (26.49) 88 (12.46) 106 (15.01) 6 (0.85) 177 (25.07) 
*Monotherapy regimens are different between Classes (χ2=39.8, p<0.001) 
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Figure 2.1. Conceptual diagram of Clinical Net Benefit latent construct.  
 
Caption: Dots represent different hypothetical CNB groups and their relative coordinates of psychiatric symptoms, 
adverse medication effects, and overall functioning. 
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Figure 2.2. Results of the Latent Class Analysis depicting the five classes of CNB.  
 
Caption: BHS, YMRS and MADRS are the Psychiatric Symptoms dimension. Tremor through Sex are the Adverse Effects dimension. QLESQ, LRIFT, GAF 
and Work Impairment are the Overall Functioning dimension. 
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Figure 2.3. Psychotropic Regimens by Class. 
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Supplemental Figure 2.1. Flowchart from original sample to current analytical sample. 
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Supplemental Figure 2.2. Make up of Psychotropic Medication regimens by Class and Regimen Type. 
 
0% 20% 40% 60% 80% 100%
Class 1
Class 2
Class 3
Class 4
Class 5
5+ Medications
Class 1
Class 2
Class 3
Class 4
Class 5
4 Medications
Class 1
Class 2
Class 3
Class 4
Class 5
3 Medications
Class 1
Class 2
Class 3
Class 4
Class 5
2 Medications
Class 1
Class 2
Class 3
Class 4
Class 5
Monotherapy
Antidepressants
Mood Stabilizers
Antipsychotics
Sedative/Hypnotics
Stimulants
Other
58 
 
 
 
 
 
 
CHAPTER 3 
The Bi-directional Relationship between Clinical Net Benefit and Medication Adherence Over 
Time in Bipolar Disorder: A Latent Transition Analysis 
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ABSTRACT 
Objectives: Poor adherence to psychotropic medication is a significant problem for individuals 
with bipolar disorder (BD), despite effective therapies. Clinicians report individuals who benefit 
from treatment over time become less adherent possibly due to perceptions that treatment is no 
longer necessary. Clinical net benefit (CNB) models the experiences individuals have while 
being treated for BD. We aimed to test whether transitions between classes of benefit occur over 
time and whether these changes are associated with adherence. 
Methods: Data come from the Systematic Treatment Enhancement Program for Bipolar 
Disorder (STEP-BD), including two years of follow up (Time 1 through 5) of participants aged 
18+ years. Latent class analysis identified distinct groups based on the intersection of the three 
factors of CNB: psychiatric symptoms (i.e., decrease in episodes), adverse effects (e.g., 
sedation), and functioning (i.e., employment, quality of life). Transitions between classes across 
the five time points was determined using latent transition analysis. Adherence was defined as 
taking 75% or more of medications as prescribed. Polypharmacy was categorized as number of 
medications taken concurrently. Associations between CNB classes, medication regimens, 
changes in both over time, and adherence were tested using multiple logistic regression adjusting 
for sociodemographic characteristics. 
Results: Five classes of CNB were identified at each time point: High, Moderately high, 
Moderate, Moderately low and Low. The lower benefit classes transitioned to higher benefit 
classes by Time 5 (probability of low benefit at Time 4 to moderate benefit at Time 5=0.86), 
while the higher benefit classes transitioned to lower benefit classes by Time 5 (probability of 
high benefit at Time 4 to moderately low benefit at Time 5=0.96), but transitioning was not 
associated with adherence. Relative to monotherapy, taking less complex regimens (three or 
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fewer) while in the higher benefit classes, were associated with lower adherence (e.g., high 
benefit at Time 2 taking two medications: OR=0.40; 95% CI: 0.20-0.81), and more complex 
regimens (four or more) in the lower benefit classes were associated with higher adherence (e.g., 
moderately low benefit at Time 2 taking five + medications: OR=1.98; 95% CI: 1.05-3.76). 
Medication regimens were nonlinearly associated with adherence; taking 3 or fewer medications 
were associated with lower adherence (e.g., three medications at Time 2: OR=0.62; 95% CI: 
0.46-0.83), taking 4 or more were associated with higher adherence (e.g., five + medications at 
Time 2: OR=1.60; 95% CI: 1.12-2.27). Adherence did not differ across classes at each time 
point. 
Conclusions: Individuals initially experiencing low CNB from their medications transitioned to 
higher CNB classes over time, with few participants in the low benefit class by Time 5. 
However, individuals receiving high benefit early in the study transitioned to the lower benefit 
classes by Time 5. This supports reports from clinicians treating individuals with BD and 
suggests psychotherapeutic methods such as psychoeducation are possible ways to increase 
adherence in individuals who are experiencing high benefit from their medications. 
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INTRODUCTION 
 Bipolar disorder (BD) is a psychiatric condition characterized by cyclical periods of 
mania and depression that affects 1-4% of the United States population.19, 126 It is one of the 
leading causes of disability adjusted life years lost in the U.S.12, 14 Due to the debilitating, chronic 
and cyclical nature of this illness, symptomatic individuals often experience high levels of 
unemployment, disability, in-patient care, medical comorbidities, and increased mortality.16, 127 
Psychotropic medications can successfully treat symptoms of BD; for example, among 
individuals who are adherent to treatment, only 37% relapse into a depression after one year,126 
and lithium monotherapy symptom recurrence rates are 40% in long term follow-up studies.30 
These individuals can be treated on an outpatient basis and remain fully functioning members of 
the general population. However, between 20 and 60% of individuals with BD are non-adherent 
over long term treatment, defined as greater than one year.36 Improving medical management of 
BD is key to reducing these negative consequences. 
To identify determinants of non-adherence, the perspective of health care providers and 
individuals with BD themselves have been examined. Health care providers have identified 
aspects of the illness itself, such as feeling well or missing the highs experienced in mania,22, 39, 40 
as well as adverse effects 44, 108 and complex regimens of multiple psychotropic medications 
taken concurrently (i.e., polypharmacy)127 as predictors of non-adherence. Predictors of non-
adherence include negative attitudes toward medication in individuals with BD, for example with 
the notion that taking medication for their illness is not normal.47 As individuals achieve 
remission, non-adherence may increase because individuals may incorrectly believe that they are 
cured or that they did not actually have BD.39  
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Providers weigh the benefits versus risks of specific medications when selecting a 
treatment regimen for individuals with BD, with symptom remission as the primary goal during 
acute episodes.32 As individuals with BD achieve remission, they then enter the maintenance 
phase of treatment.16 Guidelines indicate that effective treatments in the acute phase should be 
continued in the maintenance phase, with medication adjuncts as other symptoms arise (e.g., 
addition of an antipsychotic or antidepressant if symptoms of depression persist).128 BD is a 
chronic disorder and thus adherence to treatment must be maintained indefinitely.32 However, if 
during maintenance individuals with BD poorly adhere to their medications, this will lead to 
relapse and possible hospitalization.19 It has been found that multiple relapses leads to not only 
more episodes, but more severe symptoms during those episodes.33 
Three main factors are in play when considering the benefit of a particular medication or 
medication regimen for managing BD: psychiatric symptom reduction, low levels of adverse 
effects, and high functioning.16 These factors work synergistically, and we have developed a 
novel construct of Clinical Net Benefit (CNB) to empirical model these elements, detailed 
previously.129  
 To fully explore the associations between the CNB of medication and adherence, 
individuals must be followed over time to test the stability of these associations. Using the five-
year longitudinal Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), 
and the latent construct of CNB identified in our previous analysis, there are three goals for the 
current study: (1) to determine if membership in the CNB classes changes over time, (2) to 
determine if there is an association between the classes of CNB and adherence over time, and (3) 
to determine if the complexity of medication regimens are associated with adherence over time. 
The primary hypothesis is that individuals who initially experience high CNB during treatment 
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will become less adherent over time, and that this change in adherence will in turn reduce CNB. 
The secondary hypothesis is that as the complexity of medication regimens increases, adherence 
to those regimens will decrease over time, regardless of CNB. 
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METHODS 
Sample 
Data come from the STEP-BD study analysis. Eligibility criteria for STEP-BD included 
diagnoses of bipolar spectrum disorders (meeting DSM-IV criteria for Bipolar I Disorder, 
Bipolar II Disorder, Bipolar Not Otherwise Specified, Cyclothymic Disorder, or Schizoaffective 
Disorder Bipolar Subtype), currently in outpatient treatment for BD at a STEP-BD treatment 
center, could meet with their clinicians as scheduled for the study and could complete all study 
registration forms within three months of registration. STEP-BD was a 5-year randomized 
clinical trial (RCT) of individuals treated for bipolar spectrum disorders. It was designed to 
simulate the “real world” experiences of treatment for individuals with BD. STEP-BD was not 
solely an RCT, as eligible participants could choose to enter either the Randomized Care 
Pathways (RCPs) or Standardized Care Pathway (SCP; i.e., treatment as usual). In the RCPs, 
participants were randomly assignment to specific medications (i.e., mood stabilizers, 
antipsychotics, antidepressants or placebos) to minimize self-selection bias. If initial regimens 
were ineffective, participants moved on to subsequent medications, either randomized or 
determined by the treating physician, until an effective regimen was reached. Participants 
routinely underwent a battery of clinician- and self-administered psychological assessments. In 
addition, at each meeting the treating clinicians assessed participants using the Clinical 
Monitoring Form (CMF). This form is used as a comprehensive tool for clinicians to use during 
follow-up assessments with participants and includes information on mood episodes, medication 
use, adverse events, mental status as well as medication adherence.62 Additional details of the 
original study design are described elsewhere.52  
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 STEP-BD enrolled 4,360 participants that met these eligibility criteria for the study. This 
analysis excluded 321 participants with less than five STEP-BD assessments (approximately two 
years of active study participation), as well as those missing data on all of the components of 
CNB, the main exposure for this analysis. In addition 399 participants were excluded who were 
less than age 18 at Time 1 and all follow-ups. The final analytic sample size was 3,996 
(Supplemental Figure 3.1.). For those with incomplete data, missing values were imputed using 
Full Information Maximum Likelihood Estimation.92 
Measures 
Clinical Net Benefit 
CNB incorporates three main effects of treatment on the individual: (1) psychiatric 
symptom reduction; (2) adverse effects; and (3) overall functioning. As we indicated in Chapter 
1, CNB can be conceptualized as a 3-dimensional construct lying at the intersection of these 
axes. Individuals differentially experience these components of treatment, depicted as points in 
Figure 1.1. from Chapter 1. Our prior work in Chapter 2 used latent class analysis to empirically 
define and quantitatively measure these three dimensions of CNB, using baseline data from 
STEP-BD.  
In the current study the psychiatric symptoms dimension consisted of the Montgomery-
Asberg Depression Rating Scale (MADRS)71 and the Young Mania Rating Scale (YMRS).70 
However, due to the small sample size of the Beck Hopelessness Scale relative to the other 
measures by Time 5, we removed this assessment from the psychiatric symptoms dimension. The 
adverse effects dimension included the measures of memory difficulties, dry mouth, sexual 
dysfunction, headache, constipation, sedation, diarrhea, and tremor from the CMF.62 Finally, the 
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overall functioning dimension included the Quality of Life Enjoyment and Satisfaction 
Questionnaire (QLESQ),72 LIFE Range of Impaired Functioning Tool (LRIFT)73 three indicators 
from the Work Impact Form (WIF),52 and past week Global Assessment of Functioning (GAF)79 
score from the CMF. 
Medication 
Supplemental Table 2.3. from Chapter 2 indicates the psychotropic medication families 
making up the different regimens that participants were taking at their baseline assessment in 
STEP-BD stratified by CNB class. These medications were listed by name (either generic or 
brand) on the CMF and were recorded at each of the five assessments. All medications were 
identified and grouped into six families: (1) antidepressants, (2) mood stabilizers, (3) 
antipsychotics, (4) sedatives/hypnotics, (5) stimulants, and (6) other using the U.S. Food & Drug 
Administration National Drug Code Directory.121 Next, a medication count variable was created 
indicating whether a participant was taking one (monotherapy), two, three, four or five or more 
medications (polypharmacy).  
Adherence 
 The CMF recorded both the milligrams prescribed as well as milligrams missed for each 
medication a participant was taking in the past seven days. We calculated adherence by first 
identifying whether participants were taking each of their medications as prescribed. Then they 
were defined as adherent if 75% or more of their regimens were taken as prescribed. For 
example, if individuals were prescribed four medications in their regimens, and if they were fully 
adherent to three of the four medications then they would be defined as adherent. Participants 
who missed more than 25% of the milligrams prescribed for one or more of the medications in 
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their regimens were defined as non-adherent. Adherence defined as missing less than 25% of an 
individual’s regimen is consistent with definitions used in STEP-BD studies.83 
Standard Care or Randomized Care Pathways 
 Identification of treatment pathway was also included. STEP-BD was designed to have 
both a SCP and three RCPs. The SCP was subsequently categorized into 15 distinct pathways 
and the RCP added an additional pathway.62 Approximately 5% (N=195) of participants entered 
RCPs at Time 1, therefore we categorized entry into any SCP as one category and any RCP as 
the second category.  
Demographic Characteristics 
 Demographic characteristics included age (in years); gender; race (White, Black, and 
Other); educational attainment (≤high school, high school diploma or General Education 
Development (GED), some college, Bachelor’s degree, and Graduate or professional degree); 
current marital status (married or living as though married, divorced or separated, never married, 
or widowed); whether participants lived alone; primary residence (private home, group home or 
something else); income (greater or less than $50,000); whether participants received Social 
Security Disability Insurance (SSDI) and welfare; and employment status (employed, 
unemployed, disabled or retired/not in the labor force). 
Analytic Approach  
Analyses took place in two steps. First, five latent class analyses (LCAs) were conducted, 
one at each STEP-BD time point, to determine the number of classes that best fit the sample at 
each time point and the predicted probabilities of participant membership in each class at each of 
these time points. Second, a Latent Transition Analysis (LTA) was conducted to confirm fit for 
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the number of classes at each time point, and to identify participants’ movement between classes 
at each time point.   
Latent Class Analysis 
As described in Chapter 2, the values of the measured indicators for CNB, whether 
ordinal or continuous, were dichotomized at all time-points based on the participants’ mean 
scores at those time points, with 1=above the mean (better outcomes). Then the number of 
distinct latent classes of CNB were determined by conducting the LCA with these measures at 
each time point. To determine model fit, we compared the Akaike Information Criterion (AIC), 
Bayesian Information Criterion (BIC), Sample-Size Adjusted BIC (BICN), Bootstrapped 
Likelihood Ratio Test (BLRT) and Entropy; for each of these indices smaller values, and 
Entropy values closest to 1, indicate better relative fit.100 Measures of model fit, prevalence of 
class membership and model interpretability were all used to determine the final number of 
classes for each time point.125 Finally, most likely class membership at each time point for each 
participant was determined from their posterior probabilities identified in these LCAs.97 
Latent Transition Analysis 
The goal of LTA is to determine whether individuals in one latent class at a particular 
time point remain in the same class or transition to another latent class at a subsequent time 
point.99 The goal of this analysis is to determine if the CNB classes are static or change over 
time; for example, whether individuals in the low benefit class stay in that class over time or 
move to higher benefit classes over the course of the trial.  
The primary outcome of LTAs are transition probabilities, which are akin to posterior 
probabilities of individuals’ class membership generated from an LCA. However, in this case, 
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the transition probabilities quantify the likelihood of moving from one class to another across 
two time points.99 LTA was used to quantify three aspects of CNB change over time: (1) the best 
fitting number of latent classes, (2) the change in values of the measured indicators for each 
class, and (3) the probability of participant class membership change at each time point. LCA is a 
cross sectional analysis that determines the best fit of the number of classes at each time point. 
However, it lacks the additional information regarding probability of participants’ changing 
classes over time.99 This can result in different numbers or characteristics of classes. Therefore, 
the LCA fit for each time point was confirmed when conducting the LTA using the AIC, BIC, 
and BICN.  
We also wanted to allow for changes in values in each of the measured indicators at each 
time point in addition to participant class membership change. Therefore we did not impose 
parameter restrictions to hold the item-response probabilities equal across each time point, which 
is often done but not necessary for an LTA.99, 102 For example, a parameter restriction would hold 
the MADRS scores in the high benefit class constant over time, and would not give us the 
additional insight into whether and which direction MADRS scores changed for the high benefit 
class at subsequent time points. 
LTA is preferable to other analytical approaches for examining change over time (such as 
Repeated Measures Latent Class Analysis) because we not only wanted to determine class 
membership at each time point, but also the probability of participants changing class 
membership (i.e., transitioning) at each consecutive time point. This additional measure of 
transitioning probabilities can most effectively be determined in LTA.99, 102 
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Characterizing the Latent Classes of CNB 
The demographic characteristics, adherence to medication regimens, types of medication 
regimens (i.e., monotherapy versus polypharmacy) and membership in the SCPs or RCPs of the 
Time 1 latent classes of CNB were compared using ANOVA for continuous measures and Chi-
square analyses for categorical measures.  
Predictors of Adherence 
 To determine predictors of adherence, multiple logistic regression analyses, adjusted for 
demographic characteristics, were conducted at each of the five time points. The primary 
predictors of adherence were: (1) CNB class membership at each time point from the LCAs, and 
(2) number of medications in participants’ regimens at each time point. An additional predictor 
was changes in medication regimens from the previous time point.  
Descriptive statistics and regressions were calculated using SAS version 9.4 (SAS 
Institute Inc.). LCA and LTA were conducted using Mplus version 7.91 
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RESULTS 
 Table 3.1. describes the characteristics of the analytic sample at Time 1. The mean age 
was 40 years, 58% were female, and 91% were non-Hispanic white. The majority had an income 
less than $50,000, 15% had income from SSDI, and 23% were unemployed. Most participants 
lived with at least one other person (73%), and only 1% lived in group homes. Three out of ten 
participants took five or more medications. Three quarters of participants were adherent to their 
medication regimen at the Time 1 assessment. 
Fitting the Latent Class Analysis for Clinical Net Benefit 
 Model fit statistics indicated that both the four- and five-class models of CNB had 
comparable fit across the five time points (Supplemental Table 3.1.). At Time 1 and 4, the AIC, 
BICN and BLRT indicated better fit for the five-class model, however, at Time 2 and 3 the BIC, 
BICN and Entropy indicated better fit for the four-class model. At Time 5 , both the four- and 
five-class models had equivalent fit, although the smallest class prevalence at Time 5 for the 
four-class model was 12% (N=322) compared with the smallest class in the five-class model of 
only 2% (N=47). The best fitting model when confirmed via the LTA, was the five-class model 
at each time point with an AIC, BIC, BICN greater than the four-class model (Supplementary 
Table 3.1.). In addition, keeping the number of classes the same at each time point in the LTA 
aided the interpretability of class membership change. For example, if prevalence of a class 
reduced in size at each time point, and a greater percentage of individuals moved from that class 
to a higher benefit class, this may support the notion that over time participants’ CNB increased.  
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Characteristics of the Classes of Clinical Net Benefit 
Characteristics for the five-class model of CNB are shown in Figure 3.1. The five classes 
of CNB were: (1) high benefit (characterized by low psychiatric symptoms, low adverse effects, 
and high functioning); (2) moderately high benefit (moderate psychiatric symptoms, low adverse 
effects and moderate functioning); (3) moderate benefit (moderate psychiatric symptoms, 
moderate adverse effects and moderate functioning); (4) moderately low benefit (high psychiatric 
symptoms, low adverse effects and low functioning); and (5) low benefit (high psychiatric 
symptoms, moderate adverse effects, and low functioning). Finally, participation in the SCPs 
versus the RCPs differed across CNB classes at Time 1. Consistent with the notion that 
individuals deriving the most benefit from their current medication regimens would choose to 
stay with their current treatment, almost all (99%) of those in the high benefit class elected to 
stay in the SCPs; in contrast, 10% of the low benefit class elected to enter an RCP. 
Table 3.2. describes the CNB class prevalence and medication adherence for each CNB 
class across the five time points as well as the differences in adherence across classes at each 
time point. This table illustrates three key points: First, the high benefit class grows substantially 
over the 2-year follow up period, from 19% to 36%. These findings are consistent with the fact 
that these data are derived from a stepped treatment trial, and it is expected that providers and 
participants will make treatment changes to improve the outcomes if participants do not appear 
to be benefiting from their current medication regimens.52 Second, they are also consistent with 
the notion that individuals who are not deriving much benefit from their medications are more 
likely to drop out of the trial. At Time 1, when compared to participants who stayed through 
Time 5, those who ever dropped out during the study were less likely to have at least a 
Bachelor’s degree (N=258, 24%), less likely to have an income of $50,000 or greater (N=333, 
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33%), more likely to be unemployed (N=291, 27%), and more likely to live in a group home 
(N=17, 2%). In addition, adherence was less in individuals who ever dropped out of the study 
(71% versus 76%) and almost 42% were taking five or more medications compared with 25% 
who stayed in the study (Table 3.3.). Medication adherence ranged from 72% to 80% across 
classes and time points, and did not differ across classes at each time point, with the exception of 
Time 2 (Table 3.2.). 
Clinical Net Benefit, Medication Regimens, and Medication Adherence at Time 1 
On average, participants were taking 3 (range 1 – 12) medications at Time 1. Medication 
adherence did not differ across the classes (χ2=2.96, p=0.57) at Time 1, ranging between 72% 
and 77%. However, medication regimens did differ between classes (χ2=75.18, p<0.001). In the 
high benefit class over 60% were taking three or fewer medications. In contrast, in the low 
benefit class almost 50% were taking four or more medications.  
Latent Transition Analysis: Changes in Clinical Net Benefit over Time  
 Characteristics of the different measured indicators of CNB are also in Figure 3.1. In 
general the scores for the three dimensions of CNB remained consistent across time, with the 
greatest variability seen in the psychiatric symptoms dimension and the overall functioning 
dimension. The values on the three dimensions remained relatively stable for the high benefit, the 
moderate benefit and the low benefit classes. The moderately high benefit class saw a decrease in 
symptoms over time, while the other two dimensions remained consistent. The moderately low 
benefit class saw decreased symptoms and increased functioning over time.  
Latent Transition Analysis: Movement between Classes of Clinical Net Benefit over Time 
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Table 3.4. illustrates the latent transition probabilities of moving between classes at each 
consecutive time point. Each column and each row sum to a probability of 1.0.99 For example, 
the transitions between Time 1 and 2 illustrate that most of the movement between classes 
occurred among the moderate, moderately high and high benefit classes. For example, there was 
an 80% probability of moving from the moderate to the moderately high benefit class, and an 
85% probability of moving from the moderately high to the high benefit class. In contrast, the 
moderately low and low benefit classes were generally stable, with about a 75% probability of 
remaining in these classes. Somewhat unexpected, the high benefit class had a 79% probability 
of transitioning to the moderate benefit class; this represents the precariousness of ideal 
outcomes for this population.  
From Time 2 to 3, most of the movement between classes happened with the moderately 
high to moderately low benefit classes. The probability of moving to a lower benefit class ranged 
from 81% to 86% for these three classes. The high benefit class remained stable with a 93% 
probability of remaining in this class. The low benefit class was the only class that had an 
increase in benefit, with a probability of 84% moving to the moderately high benefit class.  
Movement from Time 3 to 4 was most notable for the increase in benefit of the two lower 
benefit classes, with an 85% probability of the low benefit class moving to the high benefit class, 
and an 88% probability of the moderately low benefit class moving up to the moderate benefit 
class. The three highest classes had probabilities of between 84% and 89% movement to a lower 
benefit class.  
Finally, from Time 4 to 5 the three lowest benefit classes had probabilities between 86% 
and 92% of moving to higher benefit classes However, the two highest benefit classes at Time 4 
had probabilities of moving to lower benefit classes at Time 5; the high benefit class had a 96% 
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probability of moving to the moderately low benefit class and the moderately high benefit class 
had a 92% probability of moving to the low benefit class.  
Additionally, change in a participant’s regimen was associated with movement between 
classes at Time 4 and 5 with 34% odds of moving to a lower benefit class at Time 4, and a 28% 
odds of moving to a lower class at Time 5. In addition, a regimen change was associated with 
32% odds of moving to a higher benefit class at Time 5 (Figure 3.2.).  
Changes in Clinical Net Benefit, Medication Regimens, and Medication Adherence 
Table 3.5. shows the relative odds of adherence across the five CNB classes over time. At 
Time 1, class membership was not associated with adherence. Over time, however, several 
patterns emerged in the relationship between CNB and adherence. Relative to the high benefit 
class, most classes had lower adherence over time. For example, compared to the high benefit 
class, the low and moderately low benefit classes had approximately 30% lower odds of 
adherence at Time 2, a trend that continued to Time 4. At Time 5, the moderately high benefit 
class had 24% lower odds of adherence when compared with the high benefit class. 
Across all time points, there was a non-linear relationship between polypharmacy and 
adherence. Compared to monotherapy, taking three or fewer medications was associated with 
lower adherence, however taking four or more medications was associated with higher 
adherence. At Time 2, 3 and 5 taking two or three medications was associated with lower 
adherence as compared to monotherapy. However, changing medication regimens, including 
adding, removing or changing a medication, was not associated with adherence over time (Time 
2: OR=0.86; 95% CI: 0.72-1.03; Time 3: OR=0.95; 95% CI: 0.78-1.16; Time 4: OR=1.07; 95% 
CI: 0.87-1.32; Time 5: OR=0.84; 95% CI: 0.68-1.04). 
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Post-hoc analysis 
Medication regimens were significantly different between the classes at Time 1, 
participants in the low benefit class were the most likely to be taking complex polypharmacy 
(four or more medications). Additionally, at Time 1 adherence across all classes of benefit did 
not differ. Therefore to further examine the association between classes of CNB and their 
medication regimens with adherence, a post hoc analysis of the association between medication 
regimens and adherence stratified by class was conducted (Table 3.6.). The post hoc analysis 
revealed that the high benefit class had a trend of lower odds of adherence over time, reaching 
significance at Time 2, 3 and 5, when prescribed less complex regimens (three medications or 
less). The low benefit class had a trend of higher odds of adherence over time, with the odds 
reaching significance at Time 1 to 3 with more complex regimens of 4 or more medications. 
Due to the high rates of dropout by Time 5, we also compared the demographic 
characteristics at Time 1 of participants who stayed in the study through Time 5 to those who 
ever dropped out of the study before Time 5. Those who dropped out of the study were different 
from those who stayed in almost all demographic and study characteristics. In addition to the 
differences noted above, individuals who dropped out of the study were also less adherent, taking 
more medications concurrently, were less likely to be in a RCP, but were actually more likely to 
be in a higher benefit class (Table 3.6.). 
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DISCUSSION 
The primary finding from this study is that membership in the classes of CNB changes 
over time even in this sample of BD patients being actively treated. On a positive note, 
participants who were receiving less benefit from their medications at the start of the trial 
transitioned to classes of increased benefit over time. This is anticipated, as the purpose of a 
stepped-treatment trial is to increase the benefit participants are receiving from their treatment.52 
However, the initial higher benefit classes transitioned to lower benefit classes over time. The 
relationship between changes in CNB and changes in adherence is complex even during this 
relatively short 2-year period. Finally, toward the conclusion of the trial, changes to medication 
regimens were associated with both positive and negative changes to CNB. These findings 
broadly support clinicians’ reported experiences while working with individuals with BD. The 
individuals who benefit from their treatment become less adherent over the long term, leading to 
less benefit from their medications, likely due to their belief that they have been cured, or never 
had BD.130  
Medication regimens were associated with adherence across time, as expected, although 
this relationship was bi-directional. Our post hoc analysis of the association between medication 
regimens and adherence stratified by class revealed that the high benefit class had lower odds of 
adherence over time. This provides further support that individuals with higher benefit over time 
become less adherent, leading to less benefit from their treatment.41  
A notable finding was that the low benefit class had a trend of higher odds of adherence 
over time in participants who were taking more complex regimens of 4 or more medications. It is 
highly likely that only when it was absolutely necessary did participants’ treating psychiatrists 
prescribe complex polypharmacy, taking into account that under-dosing has been associated with 
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higher non-adherence.16 This may also be due to differential drop out, because individuals who 
dropped out of the study were taking more complex polypharmacy regimens than those who 
remained. Nevertheless, this finding adds support to previous analyses suggesting that adherence 
likely results in better outcomes because these medications are effective treatments of BD.30, 126  
Overall adherence across classes slightly increased over time although at each time point 
adherence across classes was not different, with the exception of Time 2. This indicates that 
individuals who are receiving low benefit of their medication had the same prevalence of 
adherence as those with high benefit from their medication. This lends support to the theory of 
the association between adherence and individuals’ perspectives of necessity versus concerns of 
their treatment.43 Although participants are not greatly benefiting from their medications at Time 
1, their high levels of adherence are likely associated with their movement to higher benefit 
classes. 
Strengths and Limitations of the Study 
 Strengths of this study include the use of a randomized controlled trial that was large and 
actively followed individuals at multiple time points over two years. In addition to the 
randomized pathways, treatment as usual was also allowed which more closely replicated the 
circumstances in naturalistic studies. The wealth of rigorous psychological assessments allowed 
for detailed LCAs at each time point. Detailed information on psychotropic medications gathered 
at each time point allowed us to determine the number and make up of medication regimens 
prescribed to participants in the study. The inclusion criteria allowing for bipolar spectrum 
disorders, comorbidities, different stages of the illness, and continuation of current medications 
increased the generalizability of the results. Finally, the use of both LCA to identify the 
indicators of CNB, and LTA to quantify the likelihood of moving from one class to another 
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across time points gave us empirical results rather than a reliance on theoretical 
conceptualizations. 
These results must be tempered by the limitations of this study. The primary limitation is 
that nearly one in three participants dropped out of the trial by Time 5, and this attrition was 
differential based on medication regimen and Time 1 adherence. These individuals were less 
educated, had lower socioeconomic status, and were taking more complex medication regimens 
than individuals who remained in the study. However, this is a comparable rate of retention with 
other longitudinal RCTs.131, 132 Despite the dropout rates, by Time 5 the sample size was almost 
2,800, which indicates a very high level of power for conducting latent analysis techniques.103 
Additionally, indications of adherence by the treating clinician were not confirmed by pill bottle 
counts or blood serum levels.38 In large clinical trials, this is a common measurement of 
adherence, which makes comparison between studies easier.47 Finally, participant perceptions of 
their illness, medication treatment, and their preferences for treatment were not assessed in this 
study (e.g. Beliefs about Medicines Questionnaire).63 Therefore we can only infer participants’ 
perceptions of the benefit they are receiving from their medications by their symptom and 
functional outcomes used in the psychological assessments.  
Conclusions 
 Our findings support continued collaborative, person-centered care to optimize adherence 
for individuals with BD. Consistent with practitioners’ experiences, we found that individuals 
who initially benefit from their medication are likely to become less adherent over time, possibly 
due in part to remission and the concept of being cured.46 This also suggests that becoming well 
is not as difficult as staying well. This is surprising to find in a study such as STEP-BD which is 
designed as the “best-case” scenario with regards to support, and in which participants agreed 
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upon participation. Our findings were also consistent with the reported experiences of individual 
being treated for BD that necessity versus concerns are associated with adherence.43 Individuals 
were adherent despite low benefit from their medications, and if they maintained adherence were 
likely to experience an increase in benefit from their medications over time. Education regarding 
the course of BD as well as psychotherapy with a focus on shared decision making and positive 
alliances between individuals and their practitioners have been suggested as a way to support 
adherence in populations with BD.45, 133 However, this may need to play a greater role in helping 
individuals who are successfully recovering from BD symptoms and benefiting from their 
medications as well. Further insight into whether adherence and CNB is maintained in a 
naturalistic setting can add to our results, which may be limited due to active study participation. 
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Table 3.1. Time 1 Demographic Characteristics of the full sample and by clinical net benefit class. Includes between group significant differences using ANOVA 
or chi-square analyses. 
 Full Sample High Benefit Moderately High 
Benefit 
Moderate Benefit Moderately Low 
Benefit 
Low Benefit P value 
N (%) 3,996 744 (18.62) 940 (23.52) 410 (10.26) 1,450 (36.29) 452 (11.31)  
Age (M, SD) 40.25 (12.82) 41.99 (14.37) 39.01 (13.58) 40.99 (13.04) 39.84 (11.54) 40.55 (11.87) <0.001 
Female - no./total no. (%) 2,206/3814 (57.84) 363/710 (51.13) 508/895 (56.76) 250/397 (62.97) 818/1383 (59.15) 267/429 (62.24) <0.001 
Race - no./total no. (%)       0.356 
  White 2725/3008 (90.59) 456/510 (89.41) 659/718 (91.78) 277/299 (92.64) 1028/1144 (89.86) 305/337 (90.50)  
  African American 176/3008 (5.85) 32/510 (6.27) 37/718 (5.15) 10/299 (3.34) 79/1144 (6.91) 18/337 (5.34)  
  Other 107/3008 (3.56) 22/510 (4.31) 22/718 (3.06) 12/299 (4.01) 37/1144 (3.23) 14/337 (4.15)  
Education - no./total no. (%)       <0.001 
  Less than High School 113/3692 (3.06) 16/677 (2.36) 22/873 (2.52) 5/383 (1.31) 59/1343 (4.39) 11/416 (2.64)  
  High School/GED 553/3692 (14.98) 85/677 (12.56) 114/873 (13.06) 45/383 (11.75) 232/1343 (17.27) 77/416 (18.51)  
  Some College 1398/3692 (37.87) 196/677 (28.95) 343/873 (39.29) 132/383 (34.46) 550/1343 (40.95) 177/416 (42.55)  
  Bachelor’s Degree 979/3692 (26.52) 206/677 (30.43) 251/873 (28.75) 113/383 (29.50) 318/1343 (23.68) 91/416 (21.88)  
  Graduate Degree 649/3692 (17.58) 174/677 (25.70) 143/873 (16.38) 88/383 (22.98) 184/1343 (13.70) 60/416 (14.42)  
Marital Status - no./total no. (%)       <0.001 
  Currently Married 1381/3780 (36.53) 279/707 (39.46) 288/886 (32.51) 163/393 (41.48) 472/1368 (34.50) 179/426 (42.02)  
  Previously Married 954/3780 (25.24) 145/707 (20.51) 204/886 (23.02) 93/393 (23.66) 410/1368 (29.97) 102/426 (23.94)  
  Never Married 1385/3780 (36.64) 275/707 (38.90) 374/886 (42.21) 134/393 (34.10) 469/1368 (34.28) 133/426 (31.22)  
  Widowed 60/3780 (1.59) 8/707 (1.13) 20/886 (2.26) 3/393 (0.76) 17/1368 (1.24) 12/426 (2.82)  
Lives Alone - no./total no. (%) 1008/3775 (26.70) 175/707 (24.75) 254/885 (28.70) 108/394 (27.41) 370/1364 (27.13) 101/425 (23.76) 0.260 
Income - no./total no. (%)       <0.001 
  <$50,000 2108/3484 (60.51) 346/648 (53.40) 499/816 (61.15) 193/363 (53.17) 829/1261 (65.74) 241/396 (60.86)  
  $50,000 + 1376/3484 (39.49) 302/648 (46.60) 317/816 (38.85) 170/363 (46.83) 432/1261 (34.26) 155/396 (39.14)  
SSDI - no./total no. (%) 554/3642 (15.21) 69/668 (10.33) 110/859 (12.81) 54/377 (14.32) 238/1325 (17.96) 83/413 (20.10) <0.001 
Welfare - no./total no. (%) 67/3642 (1.84) 6/668 (0.90) 4/859 (0.47) 7/377 (1.86) 36/1325 (2.72) 14/413 (3.39) <0.001 
Employment - no./total no. (%)       <0.001 
  Employed 1747/3754 (46.54) 412/697 (59.11) 427/880 (48.52) 190/395 (48.10) 567/1358 (41.75) 151/424 (35.61)  
  Unemployed 874/3754 (23.28) 119/697 (17.07) 211/880 (23.98) 81/395 (20.51) 340/1358 (25.04) 123/424 (29.01)  
  Disabled 665/3754 (17.71) 63/697 (9.04) 126/880 (14.32) 63/395 (15.95) 313/1358 (23.05) 100/424 (23.58)  
  Other 468/3754 (12.47) 103/697 (14.78) 116/880 (13.18) 61/395 (15.44) 138/1358 (10.16) 50/424 (11.79)  
Type of Residence - no./total no. (%)       0.047 
  Private Home 3543/3705 (95.63) 650/680 (95.59) 829/875 (94.74) 357/382 (93.46) 1304/1350 (96.59) 403/418 (96.41)  
  Group Home 40/3705 (1.08) 3/680 (0.44) 15/875 (1.71) 5/382 (1.31) 13/1350 (0.96) 4/418 (0.96)  
  Other 122/3705 (3.29) 27/680 (3.97) 31/875 (3.54) 20/382 (5.24) 33/1350 (2.44) 11/418 (2.63)  
Adhere - no./total no. (%) 2,468/3282 (75.20) 456/597 (76.38) 555/734 (75.61) 297/387 (76.74) 857/1145 (74.85) 303/419 (72.32) 0.565 
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Medication Regimens - no./total no. (%)       <0.001 
  Monotherapy 631/3977 (15.87) 173/744 (23.25) 136/938 (14.50) 51/406 (12.56) 214/1445 (14.81) 57/444 (12.84)  
  Two Medications 875/3977 (22.00) 191/744 (25.67) 210/938 (22.39) 96/406 (23.65) 309/1445 (21.38) 69/444 (15.54)  
  Three Medications 760/3977 (19.11) 115/744 (15.46) 180/938 (19.19) 78/406 (19.21) 288/1445 (19.93) 99/444 (22.30)  
  Four Medications 519/3977 (13.05) 71/744 (9.54) 118/938 (12.58) 67/406 (16.50) 194/1445 (13.43) 69/444 (15.54)  
  Five + Medications 1,192/3977 (29.97) 194/744 (26.08) 294/938 (31.34) 114/406 (28.08) 440/1445 (30.45) 150/444 (33.78)  
Pathway - no./total no. (%)        
  Standardized Care 3418/3613 (94.60) 650/658 (98.78) 810/830 (97.59) 397/408 (97.30) 1156/1269 (91.10) 405/448 (90.40) <0.001 
  Randomized Care 195/3613 (5.40) 8/658 (1.22) 20/830 (2.41) 11/408 (2.70) 113/1269 (8.90) 43/448 (9.60)  
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Table 3.2. Class prevalence and prevalence of adherence at each time point, with indications of differences in 
adherence across classes at each time point from chi-square analyses. 
 Time 1 Time 2 Time 3 Time 4 Time 5 
N (%) 3996 3530 3240 2988 2785 
Class (N, %)      
High Benefit Class 744 (18.62) 590 (16.71) 776 (23.95) 1174 (39.29) 1003 (36.01) 
  Adherence 456 (76.38) 429 (80.94) 535 (78.45) 848 (79.55) 723 (79.54) 
Moderately High Benefit 940 (23.52) 1204 (34.11) 433 (13.36) 767 (25.67) 1033 (37.09) 
  Adherence 555 (75.61) 813 (77.06) 323 (80.55) 538 (76.42) 731 (76.23) 
Moderate Benefit 410 (10.26) 367 (10.40) 443 (13.67) 311 (10.41) 372 (13.36) 
  Adherence 297 (76.74) 260 (76.02) 324 (76.24) 236 (78.15) 272 (77.49) 
Moderately Low Benefit 1450 (36.29) 934 (26.46) 1277 (39.41) 496 (16.60) 332 (11.92) 
  Adherence 857 (74.85) 606 (73.54) 871 (75.35) 337 (74.56) 244 (76.25) 
Low Benefit 452 (11.31) 435 (12.32) 311 (9.60) 240 (8.03) 45 (1.62) 
  Adherence 303 (72.32) 308 (74.04) 225 (75.76) 175 (76.42) 34 (79.07) 
P-value 0.565 0.023* 0.213 0.239 0.493 
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Table 3.3. Characteristics at Time 1 of individuals who remained in the trial for at least five time points compared 
with those who ever dropped out before Time 5. Includes between group significance using ANOVA and chi-square 
analyses. 
Time 1 Time 5  
 Ever Dropped out Stayed P-value 
N, % 1211 (30.31) 2785 (69.69)  
Age (M, SD) 38.51 (12.95) 40.95 (12.71) <0.001 
Female  - no./total no. (%) 628/1104 (56.88) 1578/2710 (58.23) 0.446 
Race -  no./total no. (%)   0.009 
  White 950/1066 (89.12) 1775/1942 (91.40)  
  African American 81/1066 (7.60) 95/1942 (4.89)  
  Other 35/1066 (3.28) 72/1942 (3.71)  
Education -  no./total no. (%)   <0.001 
  Less than High School 52/1079 (4.82) 61/2613 (2.33)  
  High School/GED 173/1079 (16.03) 380/2613 (14.54)  
  Some College 443/1079 (41.06) 955/2613 (36.55)  
  Bachelor’s Degree 258/1079 (23.91) 721/2613 (27.59)  
  Graduate Degree 153/1079 (14.18) 496/2613 (18.98)  
Marital Status -  no./total no. (%)   <0.001 
  Currently Married 340/1089 (31.22) 1041/2691 (38.68)  
  Previously Married 304/1089 (27.92) 650/2691 (24.15)  
  Never Married 426/1089 (39.12) 959/2691 (35.64)  
  Widowed 19/1089 (1.74) 41/2691 (1.52)  
Lives Alone  - no./total no. (%) 283/1086 (26.06) 725/2689 (26.96) 0.570 
Income -  no./total no. (%)   <0.001 
  <$50,000 666/999 (66.67) 1442/2485 (58.03)  
  >=$50,000 333/999 (33.33) 1043/2485 (41.97)  
SSDI -  no./total no. (%) 143/1061 (13.48) 411/2581 (15.92) 0.062 
Welfare -  no./total no. (%) 25/1061 (2.36) 42/2581 (1.63) 0.137 
Employment Status -  no./total no. (%)   0.009 
  Employed 476/1079 (44.11) 1271/2675 (47.51)  
  Unemployed 291/1079 (26.97) 583/2675 (21.79)  
  Disabled 181/1079 (16.77) 484/2675 (18.09)  
  Other 131/1079 (12.14) 337/2675 (12.60)  
Residence -  no./total no. (%)   0.041 
  Private Home 1022/1083 (94.37) 2521/2622 (96.15)  
  Group Home 17/1083 (1.57) 23/2622 (0.88)  
  Other 44/1083 (4.06) 78/2622 (2.97)  
Adherence -  no./total no. (%) 546/768 (71.09) 1922/2514 (76.45) 0.003 
Pathway -  no./total no. (%)   <0.001 
  Standard Care 871/881 (98.86) 2547/2732 (93.23)  
  Randomized Care 10/881 (1.14) 185/2732 (6.77)  
Medication Regimens -  no./total no. (%)   <0.001 
  Monotherapy 203/1211 (16.76) 428/2766 (15.47)  
  Two Medications 234/1211 (19.32) 641/2766 (23.17)  
  Three Medications 166/1211 (13.71) 594/2766 (21.48)  
  Four Medications 106/1211 (8.75) 413/2766 (14.93)  
  Five + Medications 502/1211 (41.45) 690/2766 (24.95)  
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Classes -  no./total no. (%)   <0.001 
  High Benefit 258/1211 (21.30) 486/2785 (17.45)  
  Moderately High Benefit 316/1211 (26.09) 624/2785 (22.41)  
  Moderate Benefit 84/1211 (6.94) 326/2785 (11.71)  
  Moderately Low Benefit 471/1211 (38.89) 979/2785 (35.15)  
  Low Benefit 82/1211 (6.77) 370/2785 (13.29)  
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Table 3.4. a-d. Probabilities of transitions between latent classes of CNB for each pair of time points. Bold indicates 
highest probability of movement to subsequent class. 
a. Time 2     
Time 1 High Benefit 
Moderately  
High Benefit 
Moderate  
Benefit 
Moderately  
Low Benefit Low Benefit 
High Benefit 0.087 0.000 0.788 0.084 0.041 
Moderately High Benefit 0.849 0.000 0.108 0.000 0.043 
Moderate Benefit 0.005 0.805 0.016 0.062 0.112 
Moderately Low Benefit 0.009 0.027 0.206 0.721 0.038 
Low Benefit 0.064 0.086 0.025 0.049 0.776 
 
b. Time 3     
Time 2      
High Benefit 0.932 0.025 0.003 0.040 0.000 
Moderately High Benefit 0.000 0.100 0.812 0.000 0.087 
Moderate Benefit 0.058 0.026 0.001 0.849 0.066 
Moderately Low Benefit 0.000 0.015 0.036 0.093 0.855 
Low Benefit 0.080 0.840 0.017 0.000 0.062 
 
c. Time 4     
Time 3      
High Benefit 0.007 0.894 0.088 0.000 0.012 
Moderately High Benefit 0.003 0.033 0.044 0.050 0.871 
Moderate Benefit 0.079 0.000 0.000 0.880 0.041 
Moderately Low Benefit 0.039 0.113 0.835 0.000 0.014 
Low Benefit 0.850 0.000 0.100 0.025 0.025 
 
d. Time 5     
Time 4      
High Benefit 0.026 0.006 0.003 0.957 0.008 
Moderately High Benefit 0.000 0.038 0.038 0.000 0.924 
Moderate Benefit 0.000 0.918 0.019 0.063 0.000 
Moderately Low Benefit 0.874 0.000 0.078 0.048 0.000 
Low Benefit 0.011 0.045 0.863 0.052 0.030 
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Table 3.5. Results from logistic regression analyses with class membership, medication regimens and medication regimen change predicting adherence at each 
time point. 
Predicting Adherence at Time 1 Time 2 Time 3 Time 4 Time 5 
 (OR, 95% CI) (OR, 95% CI) (OR, 95% CI) (OR, 95% CI) (OR, 95% CI) 
Class (ref=High Benefit 
Class) 
     
  Moderately High Benefit 0.99 (0.74-1.31) 0.81 (0.61-1.09) 1.08 (0.77-1.52) 0.84 (0.65-1.09) 0.76 (0.59-0.97)* 
  Moderate Benefit 1.16 (0.83-1.64) 0.77 (0.54-1.12) 0.95 (0.68-1.32) 0.92 (0.65-1.31) 0.79 (0.57-1.10) 
  Moderately Low Benefit 0.91 (0.70-1.19) 0.69 (0.51-0.93)* 0.80 (0.62-1.03)‡ 0.79 (0.59-1.06) 0.77 (0.55-1.09) 
  Low Benefit 0.87 (0.63-1.21) 0.71 (0.50-0.99)* 0.75 (0.52-1.08) 0.70 (0.48-1.01)‡ 0.87 (0.37-2.05) 
Medication Regimen (ref=1)      
  Two Medications 0.86 (0.65-1.12) 0.69 (0.51-0.91)** 0.51 (0.37-0.71)** 0.94 (0.67-1.31) 0.58 (0.40-0.85)** 
  Three Medications 0.63 (0.48-0.82)** 0.62 (0.46-0.83)** 0.53 (0.38-0.74)** 0.71 (0.50-0.99)* 0.49 (0.34-0.72)** 
  Four Medications 1.41 (1.01-1.96)* 1.45 (1.01-2.09)* 1.24 (0.83-1.84) 1.43 (0.97-2.11)‡ 1.17 (0.76-1.80) 
  Five + Medications 1.28 (0.93-1.75) 1.60 (1.12-2.27)** 0.88 (0.61-1.27) 1.44 (0.99-2.09)‡ 1.04 (0.69-1.57) 
Regimen Change (ref=No)  0.86 (0.72-1.03) 0.95 (0.78-1.16) 1.07 (0.87-1.32) 0.84 (0.68-1.04) 
Values are adjusted for care pathway, age, gender, education, marital status, income, SSDI, Welfare, Employment, Residence 
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Table 3.6. Post-hoc analysis results: Odds of adherence predicted by medication regimens stratified by class for each time point. 
Predicting Adherence at Time 1 Time 2 Time 3 Time 4 Time 5 
 (OR, 95% CI) (OR, 95% CI) (OR, 95% CI) (OR, 95% CI) (OR, 95% CI) 
High Benefit      
  Regimen (ref=Monotherapy)      
    Two medications 0.70 (0.39-1.24) 0.40 (0.20-0.81)* 0.31 (0.16-0.59)** 0.91 (0.56-1.49) 0.61 (0.34-1.08)‡ 
    Three medications 0.63 (0.33-1.23) 0.36 (0.16-0.80)* 0.35 (0.17-0.70)** 0.70 (0.42-1.17) 0.46 (0.25-0.85)* 
    Four Medications 1.30 (0.55-3.10) 0.85 (0.32-2.28) 0.70 (0.29-1.67) 1.30 (0.68-2.48) 0.94 (0.44-2.01) 
    Five + Medications 1.05 (0.47-2.34) 1.37 (0.44-4.26) 1.68 (0.52-5.47) 1.15 (0.61-2.19) 0.71 (0.35-1.42) 
Moderately High Benefit      
  Regimen (ref=Monotherapy)      
    Two medications 1.01 (0.58-1.77) 0.56 (0.35-0.89)* 0.67 (0.25-1.81) 0.71 (0.36-1.41) 0.92 (0.50-1.67) 
    Three medications 0.76 (0.43-1.35) 0.70 (0.43-1.15) 0.51 (0.19-1.40) 0.80 (0.40-1.60) 0.76 (0.42-1.37) 
    Four Medications 1.37 (0.69-2.71) 1.41 (0.76-2.63) 0.78 (0.25-2.46) 1.28 (0.61-2.73) 2.71 (1.31-5.62)** 
    Five + Medications 2.30 (1.08-4.88)* 2.47 (1.15-5.33)* 0.42 (0.14-1.26) 2.09 (0.90-4.86)‡ 1.52 (0.77-3.00) 
Moderate Benefit      
  Regimen (ref=Monotherapy)      
    Two medications 0.94 (0.36-2.47) 0.73 (0.23-2.28) 0.52 (0.17-1.55) 1.31 (0.33-5.27) 0.37 (0.10-1.32) 
    Three medications 0.87 (0.31-2.39) 0.39 (0.12-1.27) 0.51 (0.17-1.51) 0.65 (0.16-2.63) 0.64 (0.18-2.35) 
    Four Medications 1.44 (0.46-4.48) 2.33 (0.61-8.98) 0.90 (0.28-2.91) 2.23 (0.47-10.65) 0.82 (0.21-3.17) 
    Five + Medications 1.14 (0.41-3.14) 1.11 (0.33-3.74) 1.38 (0.45-4.27) 1.38 (0.36-5.30) 1.23 (0.32-4.65) 
Moderately Low Benefit      
  Regimen (ref=Monotherapy)      
    Two medications 0.80 (0.50-1.27) 1.08 (0.61-1.91) 0.55 (0.33-0.91)* 1.59 (0.62-4.12) -- 
    Three medications 0.54 (0.34-0.85)** 0.84 (0.48-1.47) 0.58 (0.34-0.98)* 0.78 (0.31-1.96) -- 
    Four Medications 1.67 (0.94-2.94)‡ 2.62 (1.28-5.35)** 2.02 (1.06-3.84)* 2.48 (0.87-7.06)‡ -- 
    Five + Medications 0.85 (0.49-1.46) 1.98 (1.05-3.76)* 0.96 (0.54-1.70) 2.16 (0.80-5.86) -- 
Low Benefit      
  Regimen (ref=Monotherapy)      
    Two medications 1.12 (0.42-2.99) 1.30 (0.45-3.77) 1.25 (0.30-5.09) 1.93 (0.25-15.23) -- 
    Three medications 0.61 (0.25-1.51) 0.77 (0.27-2.18) 2.23 (0.56-8.87) 1.09 (0.17-7.12) -- 
    Four Medications 1.43 (0.52-3.92) 1.34 (0.44-4.10) 3.67 (0.88-15.39)‡ 2.71 (0.42-17.66) -- 
    Five + Medications 2.35 (0.91-6.08)‡ 2.60 (0.89-7.64)‡ 2.53 (0.70-9.10) 4.27 (0.69-26.40) -- 
Values are adjusted for care pathway, age, gender, education, marital status, income, SSDI, Welfare, Employment, Residence 
-- Sample size too small for analysis 
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Supplemental Table 3.1. Fit statistics for 4 and 5 class LCAs and 4 and 5 class LTA. 
 AIC BIC BICN BLRT Entropy Smallest Class 
(%) 
Time 1       
  4 classes 48234.41 48605.7 48418.23 408.883 0.728 11.7 
  5 classes 48156.63 48622.32 48387.18 107.781 0.646 12.3 
Time 2       
  4 classes 41246.95 41610.94 41423.47 305.253 0.689 12 
  5 classes 41180.28 41636.81 41401.68 96.668 0.611 12.4 
Time 3       
  4 classes 36059.46 36418.38 36230.91 323.342 0.676 11 
  5 classes 36044.69 36494.85 36259.72 44.776 0.602 10.6 
Time 4       
  4 classes 31421.84 31775.98 31588.51 288.119 0.65 11.5 
  5 classes 31376.04 31820.21 31585.09 75.799 0.593 8.2 
Time 5       
  4 classes 28224.47 28574.46 28387 172.43 0.598 11.6 
  5 classes 28175.8 28614.77 28379.64 78.677 0.624 1.7 
LTA       
  4 classes 175454.4 177537.5 176485.8 -- -- -- 
  5 classes 174223.6 176954.9 175575.8 -- -- -- 
AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion; BICN: Sample-Size Adjusted 
BIC; BLRT: Bootstrapped Likelihood Ratio Test 
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Figure 3.1. Classes of CNB over the course of the study. From left to right, Time 1 (a), 2 (b), 3 (c), 4 (d) and 5 (e) at the bottom. 
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Figure 3.2. Medication regimen change and the subsequent odds of changing to an increased or decreased 
CNB class at each time point. 
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Supplemental Figure 3.1. Flowchart from original sample to current analytical sample. 
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CHAPTER 4 
The Bi-directional Relationship between Clinical Net Benefit and Medication Adherence Long 
Term in Bipolar Disorder: A Latent Transition Analysis   
94 
 
ABSTRACT 
Objectives: Treatment for bipolar disorder (BD) is chronic, yet medication adherence is poor. 
Research into the long-term efficacy of psychotropic medication treatment of BD largely focuses 
on remission or relapse rather than adherence. Long-term studies rarely follow individuals more 
than two years, which does not accurately represent treatment of BD that may extend 20 years. 
Using the empirically quantified latent construct of clinical net benefit (CNB) and a three-year 
naturalistic follow-up, or treatment as usual, of individuals with BD, we tested whether classes of 
CNB changed over time and were associated with adherence to the same extent as occurred 
during two years of the active participation. 
Methods: Data come from the Systematic Treatment Enhancement Program for Bipolar 
Disorder’s (STEP-BD) 3-year naturalistic follow up (Time 5 to 8) of participants aged 18+ years, 
following two years of active participation. Latent class analysis identified distinct groups based 
on the intersection of the three factors of CNB: psychiatric symptoms (i.e., decrease in episodes), 
adverse effects (e.g., sedation), and functioning (i.e., employment, quality of life). Transitions 
between classes across the four time points was determined using latent transition analysis. 
Adherence was defined as taking 75% or more of medications as prescribed. Polypharmacy was 
categorized as number of medications taken concurrently. Associations between CNB classes, 
medication regimens, changes in both over time, and adherence were tested using multiple 
logistic regression adjusting for sociodemographic characteristics. 
Results: Four classes of CNB were identified at each time point: High, Moderate, Moderately 
low and Low. The lower benefit classes transitioned to higher benefit classes at each time point 
(e.g., probability of low benefit at Time 5 to moderate benefit at Time 6=0.93), while the higher 
benefit classes transitioned to lower benefit classes by Time 8 (e.g., probability of high benefit at 
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Time 7 to moderately low benefit at Time 8=0.79). Medication regimens were associated with 
both positive and negative changes in class (e.g., Time 7 taking 5+ medications predicted Time 8 
higher class: OR=3.75; 95% CI: 1.07-13.17). Neither the CNB classes, nor transitioning between 
them were associated with adherence, and adherence did not differ across classes at each time 
point. Relative to monotherapy, taking less complex regimens (three or fewer) was associated 
with lower adherence across Time 5 to 7 (e.g., Time 5 taking two medications: OR=0.32; 95% 
CI: 0.14-0.74).  
Conclusions: Individuals experiencing low CNB from their medications at Time 5 transitioned 
to higher CNB classes over time, while individuals receiving high benefit transitioned to the 
lower benefit classes by Time 8. This is consistent with our findings from the active participation 
phase of STEP-BD. However, class membership was not associated with adherence, and 
adherence was equivalent across classes and time points. This suggests that although CNB does 
represent experiences people are having during treatment, it does not explain why individuals 
adhere to their medications. Using CNB, individuals with low benefit from treatment can be 
identified by their clinicians and focus together on changing their treatment to increase their 
benefit, with high probability of success due to their adherence.  
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INTRODUCTION 
 Bipolar disorder (BD) only affects 4% of adults,126 but is one of the leading causes of 
disability adjusted life years lost in the U.S.12 The first line treatment for individuals 
experiencing onset or acute episodes of BD is psychotropic medication.16 Due the chronic and 
cyclical nature of BD, medication adherence is not only necessary but must often be maintained 
indefinitely. However, medication adherence to treatment is a continuing problem for individuals 
with BD, ranging from 20-70% during long term treatment (i.e., greater than one year).36, 37 Non-
adherence is associated with increasing numbers and severity of episodes leading to increased 
health care costs, disability and mortality.134, 135  
There are multiple factors believed to influence medication non-adherence for individuals 
with BD. One factor is adverse effects from medications (e.g., sedation, sexual dysfunction).43, 44 
However, the prevalence of adherence has remained relatively consistent even with the advent of 
newer generation medications (i.e., atypical antipsychotics, selective serotonin reuptake 
inhibitors, and antiepileptics) with fewer severe adverse effects, compared with older 
medications (i.e., monoamine oxidase inhibitors and typical antipsychotics).43 Another factor 
concerns the complexity of medication regimens (taking more than one medication concurrently 
or polypharmacy). Baldessarini, et al. (2008), found that 40% of individuals with BD covered by 
a large commercial health care plan were prescribed polypharmacy (defined as two or more 
psychotropic medications concurrently) between the years of 2001 and 2005.127 Finally, aspects 
of the illness itself (“feeling well”, “missing highs”) have also been identified as possibly 
associated with lower levels of adherence.22 Specifically, individuals with BD indicate that non-
adherence is related to their need to find balance between necessity of treatment versus concerns 
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about medications.43 In sum, non-adherence has multiple, intersecting determinants, and novel 
methodological approaches are needed to examine this complex relationship. 
 While the imperative of clinical trials is to demonstrate the efficacy of medications, 
studies of “long term” use of medications used to treat BD (e.g., mood stabilizers or atypical 
antipsychotics) have an average length of 6 months to two years.30, 136, 137 Additionally, non-
adherence is generally not the primary end point of interest for these studies. Instead they focus 
on time to relapse/recurrence (i.e., rehospitalization rates, time to any mood episode, total 
number of relapses) or remission (i.e., first stabilized with active drug after mood episode, 
duration of neutral mood).128, 136, 137 The studies that have identified non-adherence use multiple 
definitions of non-adherence (i.e., time to premature discontinuation for any clinical reason, 
treatment discontinuation), making comparisons difficult.49  
 Individuals with BD are often diagnosed in their early twenties,15 and thus most 
individuals will be taking medications for many decades as they age.14 Rather than evaluating 
efficacy for a relatively short period of time, to fully understand the outcomes of a typical 
treatment regimen for individuals with BD it is necessary to follow them for multiple years. The 
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) trial was designed 
to fill this gap. STEP-BD followed participants for five years. The active participation phase 
occurred during the first two years, followed by a naturalistic follow-up for three years with 
treatment-as-usual to simulate experiences by individuals with BD being treated in the general 
population.52  
In addition to medication efficacy, providers weigh the benefits versus risks of any 
medication they prescribe to individuals they treat. This follows the treatment guidelines for 
individuals with BD,16 which identifies three overarching goals of treatment: psychiatric 
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symptom reduction, low levels of adverse effects, and improved functioning. As detailed in 
Chapter 2, we have created a novel model of these aspects of treatment for BD as three 
intersecting dimensions of a latent variable we call Clinical Net Benefit (CNB). Each of these 
dimensions work synergistically and reflect the heterogeneity in benefit (and harm) experienced 
by individuals undergoing treatment for BD.  
 From our previous analyses (Chapter 3), we identified that while a substantial proportion 
of STEP-BD participants attained a high level of CNB at some point during the trial, most 
individuals did not maintain this status consistently over time. We also identified that for 
individuals with low initial levels of CNB, those who maintained adherence to their medications 
experienced an increase in their CNB over time. However, our previous study only followed 
individuals during the active-trial component of STEP-BD, over approximately two years. To 
add to the knowledge gained in our previous work, we extended this to the naturalistic follow-up 
during the final three years of STEP-BD. The overarching aims for this study are to determine if, 
during the naturalistic follow-up of STEP-BD, (1) membership in classes of CNB change over 
time, (2) the CNB classes are associated with adherence over time, and (3) the complexity of the 
medication regimens are associated with adherence over time.  
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METHODS 
Sample 
Data come from the STEP-BD study. Eligibility criteria for STEP-BD included diagnoses 
of bipolar spectrum disorders (meeting DSM-IV criteria for Bipolar I Disorder, Bipolar II 
Disorder, Bipolar Not Otherwise Specified, Cyclothymic Disorder, or Schizoaffective Disorder 
Bipolar Subtype), receiving outpatient treatment for BD at a STEP-BD treatment center at the 
time of study entrance, participants’ ability to meet with their clinicians as scheduled for the 
study and their ability to complete all study registration forms within three months of 
registration. STEP-BD was a 5-year RCT designed to simulate the “real world” experiences of 
treatment for individuals with BD. The first two years of study participation included active 
monitoring and regular meetings occurring approximately every three months. The last three 
years of the study were designed to be a naturalistic follow up, with at least one appointment per 
year during those subsequent years. Eligible participants could choose to enter either the 
Randomized Care Pathways (RCPs) where participants were randomly assignment to specific 
medications (i.e., mood stabilizers, antipsychotics, antidepressants or placebos) or Standardized 
Care Pathways (SCPs; i.e., treatment as usual). If initial regimens were ineffective, participants 
moved on to subsequent medications, either randomized or determined by their treating 
physicians, until an effective regimen was reached. Participants underwent a battery of clinician- 
and self-administered psychological assessments at each scheduled meeting that included the 
Clinical Monitoring Form (CMF). In addition to tracking psychiatric symptoms and functioning, 
this form also included clinicians’ indications of participants’ medication adherence.62 
Additional details of the original study design are described elsewhere.52 
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 This study used data from the naturalistic follow up, starting with the final active 
participation assessment and three follow ups during the last three years. STEP-BD enrolled 
4,360 participants that met eligibility criteria for the study. This analysis excluded 1,555 
participants with less than five STEP-BD assessments, and missing data on all the components of 
CNB, the main exposure for this analysis. In addition, 1,234 participants were excluded because 
they were less than 18 years of age at all time points. The final analytic sample size was 1,571 
(Supplemental Figure 4.1.). For those with incomplete data on some variables, missing values 
were imputed using Full Information Maximum Likelihood Estimation.92 
Measures 
Clinical Net Benefit 
As detailed in Chapter 2, CNB incorporates three main effects of treatment on the 
individual: (1) psychiatric symptoms; (2) adverse effects; and (3) overall functioning. CNB can 
be conceptualized as a 3-dimensional construct lying at the intersection of these axes. Individuals 
differentially experience these components of treatment and our prior work used latent class 
analysis to empirically define and quantitatively measure these three dimensions of CNB using 
baseline data from the STEP-BD.129  
The psychiatric symptoms dimension consisted of the Montgomery-Asberg Depression 
Rating Scale (MADRS)71 and the Young Mania Rating Scale (YMRS).70 The adverse effects 
dimension included the measures of memory difficulties, dry mouth, sexual dysfunction, 
headache, constipation, sedation, diarrhea, and tremor from the CMF.62 Finally, the overall 
functioning dimension included the LIFE Range of Impaired Functioning Tool (LRIFT)73 three 
indicators from the Work Impact Form (WIF) and past week Global Assessment of Functioning 
(GAF)79 score. However, due to the small sample size of the Quality of Life Enjoyment and 
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Satisfaction Questionnaire (QLESQ)72 relative to the other measures by the eighth time point, we 
removed this assessment from the overall functioning dimension. 
Medication 
Psychotropic medications were listed by name (either generic or brand) on the CMF and 
were recorded at each of the assessments. All medications were identified and grouped into six 
families: (1) antidepressants, (2) mood stabilizers, (3) antipsychotics, (4) sedatives/hypnotics, (5) 
stimulants, and (6) other using the U.S. Food & Drug Administration’s National Drug Code 
Directory. 121 Next, a medication count variable was created indicating whether a participant was 
taking one (monotherapy), two, three, four or five or more medications (polypharmacy).  
Adherence 
 The CMF was completed by the study psychiatrist at each assessment. The CMF 
recorded both the milligrams prescribed as well as milligrams missed for each medication a 
participant was taking in the past seven days.62 We calculated adherence by first identifying 
whether participants were taking each of their medications as prescribed. Then they were defined 
as adherent if less than 25% of their regimens were not taken as prescribed. For example, if an 
individual was prescribed four medications in his/her regimen, if s/he was fully adherent to four 
of the five medications then she would be defined as adherent. Participants who missed more 
than 25% of the milligrams prescribed for one or more of the medications in their regimens were 
defined as non-adherent. Adherence defined as missing less than 25% of an individual’s regimen 
is consistent with definitions used in STEP-BD studies.83 
 
 
102 
 
Demographic Characteristics 
 Demographic characteristics included age (in years); gender; race (White, Black, and 
Other); educational attainment (≤high school, high school diploma or GED, some college, 
Bachelor’s degree, and Graduate or professional degree); current marital status (married or living 
as though married, divorced or separated, never married, or widowed); whether participants lived 
alone; primary residence (private home, group home or something else); income (greater or less 
than $50,000); whether participants received Social Security Disability Insurance (SSDI) and 
welfare; and employment status (employed, unemployed, disabled or retired/not in the labor 
force). 
Standardized Care or Randomized Care Pathways 
 Individuals could choose to enter the SCPs or RCPs if they met inclusion criteria. As we 
previously found in Chapters 2 and 3, individuals who chose these different pathways were 
characteristically different. Therefore, we combined all of the RCPs into one category and all of 
the SCPs into a second category and indicated membership in either of these categories across 
the classes and time points. 
Analytic Approach  
Analyses were similar to those conducted in Chapter 3 and took place in two steps. First, 
latent class analyses (LCAs) were conducted, one for each time point, to determine the number 
of classes that best fit the sample at each time point and the predicted probabilities of participant 
membership in each class. Second, a Latent Transition Analysis (LTA) was conducted to 
confirm fit for the number of classes at each time point, and to identify participants’ movement 
between classes across adjacent time points.   
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Latent Class Analysis 
We used the same process to create the binary indicators of CNB for the LCAs as 
detailed in Chapter 2. LCA is an empirical method to determine the number of subgroups, or 
classes, of a latent variable (i.e., CNB) that exist in a sample of participants. The LCA also 
assigns individuals’ membership in these classes according to their posterior probabilities of 
symptom endorsement for each of the measures.97 To determine the number of classes that best 
fit the model at each time point, we compared the Akaike Information Criterion (AIC), Bayesian 
Information Criterion (BIC), Sample-Size Adjusted BIC (BICN), Bootstrapped Likelihood Ratio 
Test (BLRT) and Entropy;100 for each of these indices smaller values, and Entropy values closest 
to 1, indicate better relative fit. Measures of model fit, prevalence of class membership and 
model interpretability were all used to determine the final number of classes for each time 
point.97, 125 
Latent Transition Analysis 
Following the methods described in Chapter 3, we conducted the LTA to determine 
whether individuals in one latent class at each time point transition to the same class or another 
latent class at a subsequent time point. Primary outcomes of an LTA are transition probabilities, 
akin to posterior probabilities of the LCAs. These transition probabilities quantify the likelihood 
of moving from one class to another class across time points.99 The time span for this analysis is 
over a 3-year period, covering visits 5 through 8 which occurred approximately 6-12 months 
apart.52 LTA quantified three aspects of CNB change over time: (1) confirmation of the best 
fitting number of latent classes, (2) the change in values of the measured indicators for each 
class, and (3) the probability of participant class membership change at each time point. 
Confirmation of the number of classes found in the LCAs that best fit the sample, taking 
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transition between classes into account, was determined via the LTA using the AIC, BIC, and 
BICN. We allowed for changes in values in each of the measured indicators at each time point by 
not imposing parameter restrictions to hold the item-response probabilities equal across each 
time point,99, 102 as detailed in Chapter 3.  
Characterizing the latent classes of CNB 
The demographic characteristics, adherence to medication regimens, types of medication 
regimens (i.e., monotherapy versus polypharmacy), and whether participants were in the SCPs or 
RCPs of the latent classes of CNB at Time 5 were compared using ANOVA for continuous 
measures and Chi-square analyses for categorical measures.  
Predictors of Adherence 
 To determine predictors of adherence, multiple logistic regression analyses, adjusted for 
demographic characteristics, were conducted at each of the four time points. The primary 
predictors of adherence were: (1) CNB class membership at each time point from the LCAs, and 
(2) the number of medications in participants’ regimens at each time point. Additional predictors 
were: (3) change in CNB class membership from the previous time point, and (4) changes in 
medication regimens from the prior time point.  
Descriptive statistics and regressions were calculated using SAS version 9.4 (SAS 
Institute Inc.). LCA and LTA were conducted using Mplus version 7.91 
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RESULTS 
 Table 4.1. describes the characteristics of the analytic sample at Time 5 of STEP-BD, the 
end of active study participation. The mean age of participants was 43 years, 58% were female, 
and 94% were non-Hispanic white. The majority had an income less than $50,000 (56%), 17% 
had income from SSDI, and 19% were unemployed. Most participants lived with at least one 
other person (74%), and less than 1% lived in group homes (0.88%). Three out of ten 
participants took five or more medications. Over three quarters of participants were adherent to 
their medication regimen at Time 5 (78%). 
Fitting the Latent Class Analysis for Clinical Net Benefit 
 Model fit statistics indicated that the four-class models of CNB had better fit than the 
five-class models across Times 6-8, although fit was comparable between the four- and five-class 
models at Time 5 (Supplemental Table 4.1.). Additionally, the smallest class prevalence at Times 
5-7 were larger for the four-class model than the five-class model (9.3% versus 2.3% at Time 5; 
10.6% versus 6% at Time 6; and 9.4% versus 6.4% at Time 7). Class prevalence at Time 8 was 
the same for both the four- and five-class models (4.2%). However, the best fitting model when 
confirmed via the LTA, was the five-class model at each time point with an AIC, BIC, BICN 
greater than the four-class model (Supplementary Table 4.1.). Due to better interpretability of the 
four-class model because of higher class prevalence, and the utility of keeping the number of 
classes the same at each time point in the LTA to more easily identify class membership change, 
we decided to use the four-class model for the LTA.  
Characteristics of the Classes of Clinical Net Benefit 
Characteristics for the four-class model of CNB are shown in Figure 4.1. In following 
with our nomenclature from Chapters 2 and 3, the four classes of CNB were: (1) high benefit 
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(characterized by low psychiatric symptoms, low adverse effects, and high functioning); (2) 
moderate benefit (characterized by moderate psychiatric symptoms, moderate adverse effects 
and moderate functioning); (3) moderately low benefit (characterized by high psychiatric 
symptoms, low adverse effects and low functioning); and (4) low benefit (characterized by high 
psychiatric symptoms, moderate adverse effects, and low functioning). Finally, participation in 
the SCPs versus the RCPs differed across CNB classes at Time 5. As we found in Chapter 3, 
individuals deriving the most benefit from their current medication regimens would choose to 
stay with their current treatment, over 90% of those in the high benefit class elected to remain in 
the SCPs; in contrast, 18% of the moderately low benefit class elected to enter an RCP. 
Table 4.2. describes the CNB class prevalence and medication adherence for each CNB 
class across the four time points as well as the differences in adherence across classes at each 
time point. This table illustrates two key points: First, the high benefit class grew in size over the 
3-year naturalistic follow up, going from 35% to almost half (49%) of participants. These 
findings are consistent with the trajectories seen in Chapter 3, and are expected even during this 
naturalistic follow up because clinicians and participants were continuing to make treatment 
changes to improve the outcomes if participants did not appear to be benefiting from their 
medications. Second, we also see that the low benefit class is greatly reduced by Time 8, which 
suggests that individuals who are deriving less benefit from their medications may be modifying 
their regimens and seeing increased benefit from their regimens. This may also indicate that 
individuals who are not deriving benefit are dropping out of the trial, since only 33% remained in 
the trial from Time 5 through Time 8. However, there were no differences between the group 
that dropped out and those who remained except for their pathway membership at Time 5 (Table 
4.3.). Although overall adherence remained high across all time points and classes (between 75% 
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and 85%), we did see a great reduction in adherence in the low benefit class, ranging from 80% 
at Time 5 to 53% at Time 8. This corresponded with a great reduction in membership in this 
class, with only 10 people in this class at Time 8, supporting the notion that people who do not 
adhere do not derive benefit from their medications and thus remain in the low benefit class. 
Clinical Net Benefit, Medication Regimens, and Medication Adherence at Baseline 
On average, participants were taking 3.4 (range 1 – 8) medications at Time 5. Medication 
adherence did not differ across the classes (χ2=2.35, p=0.50) at Time 5, ranging between 76% 
and 80%. However, medication regimens did differ between classes (χ2=111.37, p<0.001). In the 
high benefit class 52% were taking three or fewer medications. In contrast, in the low benefit 
class over 50% were taking five or more medications.  
Latent Transition Analysis: Changes in Clinical Net Benefit over Time  
 Characteristics of the different measured indicators of CNB are in Figure 4.1. In general, 
scores for the three dimensions of CNB remained consistent across time, with the greatest 
variability seen in the adverse effects dimension and to a lesser degree in the overall functioning 
dimension. The values on the three dimensions remained relatively stable for the high benefit, the 
moderately low benefit and the low benefit classes. The low benefit class saw an increase in 
adverse effects over time, while the other two dimensions remained relatively consistent. The 
moderate benefit class saw the greatest change, with decreased adverse effects and decreased 
psychiatric symptoms by Time 8.  
Latent Transition Analysis: Movement between Classes of Clinical Net Benefit over Time 
Table 4.4. illustrates the latent transition probabilities of moving between classes at each 
consecutive time point. Each column and each row sum to a probability of 1.0. Overall, at each 
time point individuals in the low benefit class had a high probability of moving to the moderate 
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benefit class, and by Time 8 those in the moderately low benefit class had a high probability of 
moving to the high benefit class. By Time 8, individuals in both of the higher benefit classes had 
a high probability of moving to the lower benefit classes.  
Between Times 5 and 6 participants in the moderate and moderately low benefit classes 
had high probabilities of moving to lower benefit classes; 90% from the moderate to moderately 
low, and 92% from the moderately low to low benefit classes. However, participants in the low 
benefit class had a high probability (93%) of moving to the moderate benefit class. Those in the 
high benefit class had a 91% probability of staying in that class.  
Between Time 6 and Time 7, movement of the high and low benefit classes were the 
same as the previous time point; 91% of those in the high benefit class stayed in that class and 
92% of those in the low benefit class moved to the moderate benefit class. Those in the moderate 
benefit class at Time 6 again had a high probability of moving to a lower benefit class; however, 
the probability of remaining in the moderately low benefit class was 87%. 
Finally, between Times 7 and 8, members of the low benefit and the moderately low 
benefit class had a high probability of moving to a higher benefit class; 87% moving from the 
moderately low to the high benefit class and 97% moving from low to moderate benefit class. 
Both the high and moderate benefit classes had high probabilities of moving to lower benefit 
classes. 
Changes in Clinical Net Benefit, Medication Regimens, and Medication Adherence 
Table 4.5. shows the relative odds of adherence across the four CNB classes over time. In 
general, class membership was not associated with adherence, with the exception of the low 
benefit class at Time 7 which had lower odds of adherence when compared to the high benefit 
class (OR=0.32; 95% CI: 0.15-0.68). Also, changing to a lower benefit class from Time 6 to 
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Time 7 was also associated with lower adherence (OR=0.49; 95% CI: 0.26-0.91). At Time 5, 6 
and 7 taking 2 or 3 medications was associated with lower adherence compared with 
monotherapy. However, regimen change was only significantly associated with lower adherence 
at Time 7 (OR=0.64; 95% CI: 0.44-0.93). 
Post-hoc analysis 
The probabilities of movement between the classes was not explained by changing 
medication regimens. However, medication regimens were significantly different between the 
classes at Time 5; participants in the low benefit class were the most likely to be taking complex 
polypharmacy (five or more medications). Additionally, less complex medication regimens were 
associated with lower adherence. Therefore, to further explore the drivers associated with 
transitions between classes, we conducted a post hoc analysis testing whether medication 
regimens taken at each time point were associated with moving to a higher or lower benefit class 
at a subsequent time point. This post hoc analysis revealed that at Time 5 having a regimen of 
three medications and at Time 6 of five or more medications was associated with changes to a 
subsequently lower benefit class. However, at Time 7, having a medication regimen of 4 or more 
medications was associated with movement to a higher benefit class at Time 8 (Table 4.6.).  
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DISCUSSION 
 The primary finding from this study is that there is heterogeneity in CNB change over 
time during this three-year naturalistic follow-up of STEP-BD participants. The number of 
individuals in the high benefit class increased at each time point, and the prevalence of the low 
benefit class declined substantially over time. In many ways this was expected, since the goal of 
a treatment is to modify medication regimens if symptoms are not improving or adverse effects 
are not tolerable over time. However, we also observed that at the conclusion of follow-up 
individuals in the two highest benefit classes had moved to lower benefit classes, with the 
moderate benefit class moving to lower benefit classes at each time point. This suggests that 
even when a person achieves high benefit from their medical treatment, this benefit can decline 
over time.41 Finally, number of medications taken concurrently (i.e., polypharmacy) explained 
some of the transition between classes, with more complex regimens (3 or more medications) 
predicting change to either a higher or lower benefit class.  
In general, changes in CNB classes were not associated with adherence during this phase 
of the study, contrary to our primary hypothesis. These results parallel our prior findings in that 
individuals with less CNB have the same level of adherence as individuals with high CNB 
(Chapter 2 and 3). Lower numbers of medications taken concurrently (two or three medications) 
were associated with lower adherence relative to monotherapy at Times 5, 6 and 7. However, 
changes in medication regimen (i.e., adding a medication, removing a medication or changing 
from one medication to another) was not associated with adherence. 
 These findings suggest that this metric of CNB, while informed by guidelines for 
treatment of BD, do not directly drive individual differences in adherence. While this may be 
seen as a weakness of the CNB concept, there is good external validity of the CNB construct 
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(described in detail in Chapter 2); for example, individuals in the low benefit class have the 
highest prevalence of Social Security Disability Insurance (SSDI; 22%), lowest prevalence of 
employment (32%), and lowest prevalence of a Bachelor’s or graduate degree (40%). This 
suggests that individual level factors we were unable to assess in this study, such as individuals’ 
attitudes and perspectives toward treatment,43, 112 social support of family and friends,47 
psychotherapy support,45 and patient-clinician relationship,47 may have more direct impact on 
medication adherence for individuals with BD, as has been suggested in other work. 
Strengths and Limitations 
 Strengths of this study include not only the use of a randomized clinical trial, but also the 
length of time people were followed during this trial. Individuals were followed for close to the 
three years during the naturalistic follow-up. The wealth of objective information from the 
psychological assessments helped us create a robust model of CNB. In addition, information on 
medication prescriptions and adherence were recorded by clinicians using standardized 
assessments. Unlike more traditional randomized clinical trials, the inclusion criteria were very 
broad (bipolar spectrum disorders, any comorbidities, any age over 15), with numerous sites 
across the U.S., leading to greater generalizability of the results. Using LCA to identify classes 
of CNB experienced by participants in the trial and LTA to quantify the likelihood of changing 
to different classes of benefit over time, helped us rely on empirical results rather than theoretical 
conceptualizations.  
 However, there were limitations to this study that cannot be overlooked. The greatest 
limitation is the high levels of participant drop out. By the end of this analysis only 500 
participants remained, from an initial sample at Time 5 of almost 1,600. Although this is not 
uncommon for clinical trials,131, 132 this is poor when compared with observational cohort studies 
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such as the Health and Retirement Study (N=20,000, response rate=85% to 95%).138 However, 
according to the most cited guidelines 500 participants gave us enough power to complete the 
LCAs and LTA analyses which require a minimum sample size of 200.103 In addition, those who 
remained in the study from Time 5 to Time 8 did not differ when compared to those who 
dropped out of the study, therefore the findings for this cohort are not strongly influenced by 
differential loss to follow-up. This level of dropout, and missing data from the QLESQ, restricted 
the measures we could use for the LCA. Finally, participants’ perspectives of their medications 
were not analyzed in this study. We can only infer that they are receiving benefit or lack thereof, 
but do not know if they perceive they are subjectively doing “better”, and whether they associate 
that with their treatment.  
Conclusions 
 Our findings suggest more research into person-centered factors will likely shed light on 
aspects of adherence not easily measured through psychological assessments. Other studies have 
suggested additional factors such as personality, locus of control, perceptions of one’s illness and 
treatment, and rapport between clinicians and individuals they treat may play a significant role in 
driving adherence.47 This is most obvious in our findings that individuals who are experiencing 
low benefit from their medications are adherent to the same extent as individuals experiencing 
high benefit. Subjective reports from individuals achieving different levels of benefit from their 
medications would be a highly valuable next step. Further examination into the drivers of 
adherence in individuals who are not benefiting from their treatment will inform future treatment 
strategies improving the experiences of outcomes of these individuals. 
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Table 4.1. Demographic characteristics of the sample at Time 5 and by clinical net benefit class, at the end of active monitoring. Includes between group 
differences from ANOVA and chi-square analyses at P-values 
 Full Sample High Benefit Moderate Benefit Moderately Low 
Benefit 
Low Benefit P value 
N (%) 1571 549 (34.95) 134 (8.53) 681 (43.35) 207 (13.18)  
Age (M, SD) 42.60 (12.29) 42.42 (13.06) 44.28 (12.93) 42.20 (11.92) 43.35 (10.84) 0.255 
Female - no./total no. (%) 901/1556 (57.90) 315/544 (57.90) 77/132 (58.33) 378/676 (55.92) 131/204 (64.22) 0.218 
Race - no./total no. (%)      0.143 
  White 871/928 (93.86) 265/288 (92.01) 65/70 (92.86) 430/449 (95.77) 111/121 (91.74)  
  African American 31/928 (3.34) 12/288 (4.17) 1/70 (1.43) 13/449 (2.90) 5/121 (4.13)  
  Other 26/928 (2.80) 11/288 (3.82) 4/70 (5.71) 6/449 (1.34) 5/121 (4.13)  
Education - no./total no. (%)      0.002 
  Less than High School 24/1481 (1.62) 7/519 (1.35) 2/120 (1.67) 10/646 (1.55) 5/196 (2.55)  
  High School/GED 213/1481 (14.38) 59/519 (11.37) 15/120 (12.50) 105/646 (16.25) 34/196 (17.35)  
  Some College 505/1481 (34.10) 156/519 (30.06) 33/120 (27.50) 237/646 (36.69) 79/196 (40.31)  
  Bachelor’s Degree 427/1481 (28.83) 164/519 (31.60) 40/120 (33.33) 180/646 (27.86) 43/196 (21.94)  
  Graduate Degree 312/1481 (21.07) 133/519 (25.63) 30/120 (25.00) 114/646 (17.65) 35/196 (17.86)  
Marital Status - no./total no. (%)      0.035 
  Currently Married 643/1551 (41.46) 228/543 (41.99) 65/131 (49.62) 252/673 (37.44) 98/204 (48.04)  
  Previously Married 377/1551 (24.31) 122/543 (22.47) 28/131 (21.37) 173/673 (25.71) 54/204 (26.47)  
  Never Married 505/1551 (32.56) 181/543 (33.33) 36/131 (27.48) 239/673 (35.51) 49/204 (24.02)  
  Widowed 26/1551 (1.68) 12/543 (2.21) 2/131 (1.53) 9/673 (1.34) 3/204 (1.47)  
Lives Alone - no./total no. (%) 407/1551 (26.24) 144/543 (26.52) 27/131 (20.61) 188/674 (27.89) 48/203 (23.65) 0.281 
Income - no./total no. (%)      <0.001 
  <$50,000 808/1435 (56.31) 242/503 (48.11) 60/124 (48.39) 398/619 (64.30) 108/189 (57.14)  
  $50,000 + 627/1435 (43.69) 261/503 (51.89) 64/124 (51.61) 221/619 (35.70) 81/189 (42.86)  
SSDI - no./total no. (%) 251/1465 (17.13) 49/508 (9.65) 18/120 (15.00) 140/641 (21.84) 44/196 (22.45) <0.001 
Welfare - no./total no. (%) 23/1465 (1.57) 1/508 (0.20) 2/120 (1.67) 14/641 (2.18) 6/196 (3.06) 0.014 
Employment - no./total no. (%)      <0.001 
  Employed 754/1543 (48.87) 326/541 (60.26) 76/129 (58.91) 287/671 (42.77) 65/202 (32.18)  
  Unemployed 293/1543 (18.99) 95/541 (17.56) 16/129 (12.40) 138/671 (20.57) 44/202 (21.78)  
  Disabled 279/1543 (18.08) 38/541 (7.02) 20/129 (15.50) 156/671 (23.25) 65/202 (32.18)  
  Other 217/1543 (14.06) 82/541 (15.16) 17/129 (13.18) 90/671 (13.41) 28/202 (13.86)  
Type of Residence - no./total no. (%)      0.0940 
  Private Home 1437/1485 (96.77) 501/519 (96.53) 116/121 (95.87) 630/649 (97.07) 190/196 (96.94)  
  Group Home 13/1485 (0.88) 2/519 (0.39) 0 7/649 (1.08) 4/196 (2.04)  
  Other 35/1485 (2.36) 16/519 (3.08) 5/121 (4.13) 12/649 (1.85) 2/196 (1.02)  
Adhere - no./total no. (%) 1115/1432 (77.86) 392/493 (79.51) 99/129 (76.74) 466/612 (76.14) 158/198 (79.80) 0.503 
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Medication Regimens - no./total no. (%)      <0.001 
  Monotherapy 137/1550 (8.84) 73/546 (13.37) 7/131 (5.34) 45/670 (34.35) 11/203 (5.42)  
  Two Medications 338/1550 (21.81) 162/546 (29.67) 19/131 (14.50) 137/670 (20.45) 20/203 (9.85)  
  Three Medications 331/1550 (21.35) 106/546 (19.41) 30/131 (22.90) 167/670 (24.93) 28/203 (13.79)  
  Four Medications 280/1550 (18.06) 77/546 (14.10) 30/131 (22.90) 133/670 (19.85) 40/203 (19.70)  
  Five + Medications 464/1550 (29.94) 128/546 (23.44) 45/131 (34.35) 187/670 (27.91) 104/203 (51.23)  
Pathway - no./total no. (%)      <0.001 
  Standardized Care 1299/1503 (86.43) 474/521 (90.98) 119/133 (89.47) 525/642 (81.78) 181/207 (87.44)  
  Randomized Care 204/1503 (13.57) 47/521 (9.02) 14/133 (10.53) 117/642 (18.22) 26/207 (12.56)  
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Table 4.2. Class prevalence and prevalence of adherence at each time point, with significance of differences in 
adherence across classes at each time point. 
 Time 5 Time 6 Time 7 Time 8 
N (%) 1571 1152 802 515 
Class (N, %)     
High Benefit 549 (34.95) 483 (41.93) 366 (45.64) 253 (49.13) 
  Adherence 392 (79.51) 351 (80.69) 274 (84.57) 173 (75.22) 
Moderate Benefit 134 (8.53) 104 (9.03) 64 (7.98) 88 (17.09) 
  Adherence 99 (76.74) 79 (79.00) 50 (80.65) 66 (79.52) 
Moderately Low Benefit 681 (43.35) 448 (38.89) 248 (30.92) 153 (29.71) 
  Adherence 466 (76.14) 320 (79.01) 185 (79.06) 109 (74.66) 
Low Benefit 207 (13.18) 117 (10.16) 124 (15.46) 21 (4.08) 
  Adherence 158 (79.80) 94 (82.46) 81 (69.23) 10 (52.63) 
P-value 0.503 0.833 0.005* 0.113 
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Table 4.3. Characteristics of individuals who remained in the trial for at least eight time points compared with those 
who ever dropped out after Time 5. Between group differences from ANOVA and chi-square analyses are indicated 
as P-values. 
Time 5 Time 8  
 Dropped out Stayed P-value 
N, % 1056 (67.22) 515 (32.78)  
Age (M, SD) 42.18 (12.42) 43.45 (11.98) 0.055 
Female  - no./total no. (%) 595/1044 (56.99) 306/512 (59.77) 0.298 
Race -  no./total no. (%)   0.839 
  White 550/585 (94.02) 321/343 (93.59)  
  African American 20/585 (3.42) 11/343 (3.21)  
  Other 15/585 (2.56) 11/343 (3.21)  
Education - no./total no. (%)   0.091 
  Less than High School  20/1022 (1.96) 4/459 (0.87)  
  High School/GED 150/1022 (14.68) 63/459 (13.73)  
  Some College 361/1022 (35.32) 144/459 (31.37)  
  Bachelor’s Degree 292/1022 (28.57) 135/459 (29.41)  
  Graduate Degree 199/1022 (19.47) 113/459 (24.62)  
Marital Status - no./total no. (%)   0.794 
  Currently Married  432/1038 (41.62) 211/513 (41.13)  
  Previously Married  252/1038 (24.28) 125/513 (24.37)  
  Never Married  339/1038 (32.66) 166/513 (32.36)  
  Widowed 15/1038 (1.45) 11/513 (2.14)  
Lives Alone - no./total no. (%) 280/1038 (26.97) 127/513 (24.76) 0.350 
Income   0.496 
  <$50,000 546/959 (56.93) 262/476 (55.04)  
  >=$50,000 413/959 (43.07) 214/476 (44.96)  
SSDI - no./total no. (%) 172/1010 (17.03) 79/455 (17.36) 0.876 
Welfare - no./total no. (%) 18/1010 (1.78) 5/455 (1.10) 0.330 
Employment Status - no./total no. (%)   0.129 
  Employed 503/1032 (48.74) 251/511 (49.12)  
  Unemployed 210/1032 (20.35) 83/511 (16.24)  
  Disabled 185/1032 (17.93) 94/511 (18.40)  
  Other 134/1032 (12.98) 83/511 (16.24)  
Residence - no./total no. (%)   0.301 
  Private Home 988/1026 (96.30) 449/459 (97.82)  
  Group Home 10/1026 (0.97) 3/459 (0.65)  
  Other 28/1026 (2.73) 7/459 (1.53)  
Adherence - no./total no. (%) 736/958 (76.83) 379/474 (79.96) 0.179 
Pathway - no./total no. (%)   <0.001 
  Standard Care 949/999 (94.99) 350/504 (69.44)  
  Randomized Care 50/999 (5.01) 154/504 (30.56)  
Medication Regimens - no./total no. (%)   0.267 
  Monotherapy 102/1052 (9.70) 35/498 (7.03)  
  Two Medications 221/1052 (21.01) 117/498 (23.49)  
  Three Medications 219/1052 (20.82) 112/498 (22.49)  
  Four Medications 186/1052 (17.68) 94/498 (18.88)  
  Five + Medications 324/1052 (30.80) 140/498 (28.11)  
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Classes - no./total no. (%)   0.148 
  High Benefit 381/1056 (36.08) 168/515 (32.62)  
  Moderate Benefit 98/1056 (9.28) 36/515 (6.99)  
  Moderately Low Benefit 443/1056 (41.95) 238/515 (46.21)  
  Low Benefit 134/1056 (12.69) 73/515 (14.17)  
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Table 4.4. a-c. Probabilities of latent transitions between classes of CNB for each pair of time points. Bold indicates 
highest probabilities of transitioning. 
a. Time 6    
Time 5 High Benefit 
Moderate  
Benefit 
Moderately  
Low Benefit Low Benefit 
High Benefit 0.905 0.000 0.000 0.095 
Moderate Benefit 0.052 0.051 0.897 0.000 
Moderately Low Benefit 0.005 0.079 0.000 0.916 
Low Benefit 0.002 0.928 0.024 0.046 
 
b. Time 7    
Time 6     
High Benefit 0.911 0.062 0.000 0.027 
Moderate Benefit 0.029 0.056 0.006 0.908 
Moderately Low Benefit 0.067 0.005 0.872 0.056 
Low Benefit 0.019 0.918 0.005 0.059 
 
c. Time 8    
Time 7     
High Benefit 0.173 0.023 0.794 0.009 
Moderate Benefit 0.000 0.008 0.000 0.992 
Moderately Low Benefit 0.866 0.134 0.000 0.000 
Low Benefit 0.016 0.966 0.000 0.018 
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Table 4.5. Results of logistic regression analyses predicting adherence at each time point. Also shown is prediction of class change when medication regimens 
changed (either an increase or decrease in number of medications taken, or a change of medication). 
Predicting Adherence at Time 5 Time 6 Time 7 Time 8 
 (OR, 95% CI) (OR, 95% CI) (OR, 95% CI) (OR, 95% CI) 
Class (ref=High Benefit 
Class) 
    
  Moderate Benefit 0.63 (0.33-1.21) 0.67 (0.30-1.54) 0.63 (0.23-1.70) 1.41 (0.61-3.29) 
  Moderately Low Benefit 1.07 (0.70-1.66) 0.86 (0.52-1.43) 0.66 (0.34-1.28) 1.35 (0.71-2.58) 
  Low Benefit 1.22 (0.65-2.28) 1.14 (0.51-2.54) 0.32 (0.15-0.68)** 0.51 (0.14-1.80) 
Change in Class (ref=No)     
  Higher Benefit -- 0.92 (0.53-1.57) 1.42 (0.64-3.16) 0.91 (0.49-1.71) 
  Lower Benefit -- 1.35 (0.67-2.74) 0.49 (0.26-0.91)* 0.75 (0.32-1.75) 
Medication Regimen (ref=1)     
  Two Medications 0.32 (0.14-0.74)** 0.46 (0.20-1.04)‡ 0.84 (0.36-1.96) 0.68 (0.32-1.44) 
  Three Medications 0.35 (0.15-0.81)* 0.54 (0.24-1.23) 0.50 (0.22-1.12)‡ 0.55 (0.27-1.14) 
  Four Medications 1.20 (0.46-3.12) 0.90 (0.37-2.16) 0.95 (0.40-2.23) 1.64 (0.73-3.64) 
  Five + Medications 0.71 (0.30-1.71) 0.93 (0.39-2.17) 0.82 (0.36-1.86) 0.90 (0.43-1.87) 
Regimen Change (ref=No)  1.08 (0.28-4.20) 0.64 (0.44-0.93)* 0.87 (0.60-1.25) 
Values are adjusted for care pathway, age, gender, race, education, marital status, income, SSDI, Welfare, Employment, 
Residence 
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Table 4.6. Results of logistic regression predicting change to a higher or lower benefit class by prior time point medication regimen. 
Prior Time Point 
Medication Regimen (ref=1) 
Time 6 Time 7 Time 8 
 Higher Lower Higher Lower Higher Lower 
Two Medications 1.43 (0.51-3.99) 2.33 (0.48-11.38) 1.11 (0.34-3.62) 3.64 (0.42-31.50) 2.47 (0.66-9.33) 2.39 (0.41-14.05) 
Three Medications 1.68 (0.61-4.63) 3.82 (0.82-17.84)‡ 1.07 (0.34-3.43) 4.42 (0.52-37.28) 2.27 (0.63-8.21) 2.40 (0.43-13.35) 
Four Medications 1.70 (0.61-4.78) 2.33 (0.47-11.52) 1.62 (0.50-5.21) 4.65 (0.54-40.29) 3.52 (0.94-13.23)‡ 2.19 (0.36-13.30) 
Five + Medications 1.79 (0.66-4.88) 2.30 (0.48-10.96) 0.93 (0.29-2.97) 6.75 (0.81-56.20)‡ 3.75 (1.07-13.17)* 2.70 (0.50-14.42) 
Values are adjusted for care pathway, age, gender, race, education, marital status, income, SSDI, Welfare, Employment, Residence 
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Supplemental Table 4.1. Fit statistics for 4 and 5 class LCAs at each time point, and 4 and 5 class LTA. 
 AIC BIC BICN BLRT Entropy Smallest Class (%) 
Time 5       
  4 classes 18108.410 18403.181 18228.458 69.889 0.700 9.30 
  5 classes 18073.861 18443.664 18224.466 62.550 0.703 2.30 
Time 6       
  4 classes 13312.03 13589.74 13415.04 90.728 0.733 10.60 
  5 classes 13303.97 13652.37 13433.21 36.058 0.699 6.00 
Time 7       
  4 classes 9369.76 9627.551 9452.895 49.037 0.661 9.40 
  5 classes 9355.647 9679.058 9459.944 42.113 0.682 6.40 
Time 8       
  4 classes 5915.012 6148.441 5973.861 42.817 0.719 4.20 
  5 classes 5919.633 6212.481 5993.463 23.379 0.729 4.20 
LTA       
  4 classes 44627.21 45951.00 45166.34 -- -- -- 
  5 classes 44393.54 46130.01 45100.73 -- -- -- 
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Supplemental Table 4.2. Families of medications making up different regimens taken by each class at Time 5. 
 
 
 
 
  
 Antidepressant  Mood Stabilizer  Antipsychotic  Sedative/Hypnotic Stimulant  Other 
High Benefit       
  Monotherapy (N=73) 9 (12.33) 55 (75.34) 4 (5.48) -- -- 5 (6.85) 
  Two Medications (N=162) 54 (16.67) 178 (54.94) 50 (15.43) 12 (3.70) 3 (0.93) 27 (8.33) 
  Three Medications (N=106) 62 (19.50) 139 (43.71) 39 (12.26) 24 (7.55) 6 (1.89) 48 (15.09) 
  Four Medications (N=77) 50 (16.13) 116 (37.42) 46 (14.84) 33 (10.65) 2 (0.65) 63 (20.32) 
  Five + Medications (N=98) 64 (13.06) 139 (28.37) 55 (11.22) 52 (10.61) 6 (1.22) 186 (34.13) 
Moderate Benefit       
  Monotherapy (N=7) 1 (14.29) 6 (85.71) -- -- -- -- 
  Two Medications (N=19) 8 (21.05) 22 (57.89) 2 (5.26) 1 (2.63) -- 5 (13.16) 
  Three Medications (N=30) 12 (13.33) 38 (42.22) 15 (16.67) 5 (5.56) -- 20 (22.22) 
  Four Medications (N=30) 22 (18.33) 44 (36.67) 8 (6.67) 12 (10.00) 1 (0.83) 33 (27.50) 
  Five + Medications (N=45) 24 (10.67) 67 (29.78) 24 (10.67) 22 (9.78) 2 (0.89) 86 (38.22) 
Moderately Low Benefit       
  Monotherapy (N=46) 2 (4.35) 30 (65.22) 11 (23.91) 1 (2.17) -- 2 (4.35) 
  Two Medications (N=137) 48 (17.52) 157 (57.30) 29 (10.58) 14 (5.11) -- 26 (9.49) 
  Three Medications (N=167) 101 (20.16) 211 (42.12) 81 (16.17) 46 (9.18) 6 (1.20) 56 (11.18) 
  Four Medications (N=133) 108 (20.30) 212 (39.85) 68 (12.78) 54 (10.15) 5 (0.94) 85 (15.98) 
  Five + Medications (N=146) 108 (14.79) 225 (30.82) 88 (12.05) 100 (13.70) 4 (0.55) 205 (28.08) 
Low Benefit       
  Monotherapy (N=11) -- 8 (72.73) 2 (18.18) -- -- 1 (9.09) 
  Two Medications (N=20) 12 (30.00) 20 (50.00) 2 (5.00) 5 (12.50) -- 1 (2.50) 
  Three Medications (N=28) 16 (19.05) 36 (42.86) 7 (8.33) 13 (15.48) -- 12 (14.29) 
  Four Medications (N=40) 30 (18.75) 59 (36.88) 16 (10.00) 21 (13.13) -- 34 (21.25) 
  Five + Medications (N=104) 87 (16.73) 175 (33.65) 68 (13.08) 67 (12.88) 3 (0.58) 120 (23.08) 
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Figure 4.1. a-d. CNB LCAs for Time 5 (a), Time 6 (b), Time 7 (c) and Time 8 (d).  
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Supplemental Figure 4.1. Flowchart from original sample to current analytical sample. 
 4,360 enrolled in 
STEP-BD 
2,805 completed at 
least one psychological 
assessment at time 5 
1,555 did not complete 
psychological 
assessment at time 5 
1,571 18+ years of age 
at time 5 
1,234 < 18 years of age 
at time 5 and  
follow-ups 
125 
 
 
 
 
 
 
CHAPTER 5 
Afterword 
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This chapter provides a brief overview of the results from each of the three empirical 
papers, discusses the clinical and public health implications of these findings, and provides 
guidance for next steps in research. 
 
Chapter 2: Identifying clinical net benefit among individuals being treated for bipolar disorder 
 The objective of this first analysis was to create the Clinical Net Benefit (CNB) construct 
and determine its external validity using the baseline data from the Systematic Treatment 
Enhancement Program for Bipolar Disorder (STEP-BD). In this analysis we used baseline 
measures from STEP-BD to create a latent of the three dimensions of CNB: psychiatric 
symptoms, adverse effects and overall functioning. This latent construct of CNB was created 
using a two-step procedure. First, exploratory factor analysis (EFA) was used to reduce the 
number of measures in the CNB construct to only those necessary to define each of the three 
dimensions. Second, latent class analysis (LCA) was used to empirically identify distinct classes 
of CNB based on the clustering of responses on these three dimensions. This construct illustrated 
the heterogeneity in CNB experienced by individuals being treated for BD, with five classes 
(high benefit [N=889, 23.8%], moderately high benefit [N=961, 25.7%], moderate benefit 
[N=432, 11.6%], moderately low benefit [N=1010, 27.0%], and low benefit [N=446, 11.93%]) 
identified as the best fit to the data. These classes appeared externally valid in that individuals 
differed in terms of sociodemographic characteristics such as education (high benefit class: 
highest level of graduate degree (23.6%); highest employment (57.1%); low benefit class: highest 
SSDI (21.3%); highest unemployment (27.8%)). An unexpected finding was that the prevalence 
of medication adherence did not differ across the classes at baseline. This indicates that even 
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groups of individuals with low apparent CNB are just as likely to adhere to their medications as 
people with high apparent CNB. 
Chapter 3: Change in clinical net benefit and short-term medication adherence 
 The objectives of this second analysis were to examine whether the classes of CNB 
changed over time, whether individuals transitioned between classes, and whether these changes 
affected adherence. In this analysis we used latent transition modeling to estimate change in 
CNB over the active treatment phase of STEP-BD (approximately two years). We found that 
transitioning between CNB classes was common, and that individuals in the lowest benefit 
classes moved to higher benefit classes as the trial progressed. However, by the end of the 2-year 
period individuals in the higher benefit classes were transitioning to lower benefit classes. We 
also found that as time passed, the higher benefit classes had lower odds of adherence when 
taking fewer medications concurrently when compared to monotherapy, and the lower benefit 
classes had higher odds of adherence when taking more medications concurrently when 
compared to monotherapy. An unexpected finding was that when compared to monotherapy, 
individuals taking 4 or more medications had higher odds of adherence than individuals taking 
three or fewer medications. Finally, as we saw in Chapter 2, the classes of CNB were similar in 
their adherence rates at each time point, contrary to our expectations. 
Chapter 4: Change in clinical net benefit and long-term medication adherence 
 The objective of this third analysis was to determine whether our findings of CNB classes 
changing over time, and their association with adherence found in Chapter 3 held during the 
naturalistic follow-up in STEP-BD (approximately 3 years). This analysis showed that transitions 
between CNB classes were similar in the 3-year naturalistic follow-up period to those in the 
128 
 
active participation phase of the study. Individuals in the lower benefit classes transitioned to 
higher benefit classes by the conclusion of the study. As with the earlier chapters, classes of 
CNB were not associated with adherence in a systematic way. Medication regimens were 
associated with adherence in much the same manner as in Chapter 3, with individuals taking 
three or fewer medications concurrently having lower odds of adherence relative to 
monotherapy. Complexity of medication regimens predicted change to higher or lower benefit 
classes.  
 
Implications and Limitations 
 Through the identification, creation, and testing of the CNB construct we have looked 
beyond the factors of psychiatric symptoms, adverse effects and overall functioning experienced 
by individuals with BD. By integrating these three concepts and applying that construct to a large 
sample of participants, we have identified individuals who adhere but are not benefitting from 
their treatment. We can postulate that these individuals may perceive they are currently 
benefitting from their treatment as compared to previous experiences before entering STEP-BD, 
which could be supporting their adherence. These individuals also may not be aware that there 
are newer medications with fewer side effects to which they could switch for their quality of life 
to increase.  
 If we want a more person-centered approach to treating individuals with BD that will lead 
to a higher quality of life, we need to identify and work with individuals such as these. They 
have a wealth of insight to provide clinicians as to why they adhere and what they perceive as 
benefits from their treatment. They can inform person-centered treatment that may lead to higher 
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levels of adherence and quality of life for a broader range of individuals. Increasing public health 
for individuals with BD can start by focusing on what we can learn from these individuals. These 
individuals were more likely to be taking 4 or more medications concurrently, which puts them 
at high risk for development of chronic conditions such as obesity and cardiovascular disease. 
With a focus on the health of these individuals and involving them in their care, we can test and 
enhance our understanding and use of person-centered care for individuals with BD.  
 Latent variable modeling is a flexible analytic approach to quantifying multiple aspects 
(i.e., psychiatric symptoms, adverse effects, and overall functioning) of the individual’s 
experience while being treated for BD. The latent construct of CNB was informed by clinical 
guidelines and research on clinical impressions and patient insights to treatment. This construct 
highlights the substantial heterogeneity in CNB for this disorder. Using this novel construct, we 
identified a group of individuals who experienced low benefit from their treatment, but were 
adherent to the same extent as those with high benefit. This group that may have distinct clinical 
needs from others treated for BD, including the need for more attention to medication dosage or 
more rapid regimen changes to achieve a clinical response. 
 As has been suggested by clinicians treating individuals with BD, those who initially 
benefitted from their treatment experienced a decrease in CNB over time. This may be due in 
part to lower adherence when individuals in the high CNB class were taking fewer medications 
concurrently, as was found in Chapter 3, or changes in aspects of CNB itself, such as increases in 
adverse effects as can be seen in the lower benefit classes at each time point in Chapter 3 Figure 
3.1. However, this decrease in CNB may also be due to decreased effectiveness of the treatment 
they are receiving (e.g., tachyphylaxis: developing tolerance to antidepressant medication, or 
narrow therapeutic indices that restrict continued titration of the medication to retain 
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effectiveness).31, 139 This was suggested during the naturalistic follow up where adherence rates 
were the same across classes and time points, there was no association between medication 
regimen change and class change, yet individuals in the higher benefit classes moved to lower 
benefit classes by the end of this phase. 
 However, due to the longer time intervals between follow-up assessments during the 
naturalistic phase of the trial (i.e., assessments occurred every 12 months instead of every 3 
months as during the active phase of the trial), our measure of adherence may have been less 
valid for this portion of the analysis. Participants were asked about their medication use for the 
past week, which likely overestimated the prevalence of adherence when the time between 
appointments was from six and twelve months. 
 The dropout rates during the active phase of the trial (Time 1 through 5) and the many 
differences between individuals who dropped out and individuals who remained also tempers the 
conclusions that can be made from our findings. Overall high dropout rates lead to bias toward 
the null. However, missingness was not at random. Individuals who dropped out before Time 5 
were less likely to be adherent, more likely to be taking 5 + medications concurrently, and more 
likely to be in the high benefit class. This biases our results away from the null with regards to 
adherence in the overall sample, and away from the null with regards to adherence in the high 
benefit class. In addition, relationships between adherence and medication regimens would be 
biased away from the null for individuals taking 5 + medications concurrently. There was a high 
dropout rate during the naturalistic follow-up (Time 5 through 8) as well, although there were no 
demographic differences between participants who stayed and who dropped out during that time 
period. This non-differentially biases our results toward the null.   
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Finally, despite being theoretically grounded in clinical guidelines for CNB and having 
external validity, the construct of CNB was generally not related to medication adherence. This 
was contrary to expectations, but even though this core hypothesis was not supported, these null 
results do provide important information. Foremost, they suggest that something outside of CNB 
is driving adherence, at least in our sample. As discussed previously, there are many aspects of 
clinical care that could not be examined in this study, including subjective measures of 
participants’ opinions about taking their medications, the relationship between clinicians and 
those they treat for BD, and past changes in relative functioning before they began the trial. This 
may be particularly true with participants in our analyses who were approximately 40 years of 
age. Onset of BD takes place when people are approximately 20 years of age. This suggests that 
our sample may have been receiving treatment for BD for 20 years or more before STEP-BD 
began, and those care experiences and history may be stronger determinants of contemporary 
adherence than concurrent symptoms, adverse effects, and functioning.  
Selection bias is also a concern in any RCT. Individuals who participate in clinical trials 
are different from those who do not in a myriad of ways, which reduces the generalizability of 
the results. In addition, even though this was technically a RCT, the vast majority of participants 
elected to remain in the Standard Care Pathways (i.e., treatment as usual); this suggests they 
were satisfied with their medication regimens at baseline, since they were unwilling to “roll the 
dice” so to speak and make a change. It is also unlikely that individuals who were not adherent 
would be receiving regular outpatient care.  
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Next Steps 
 A number of directions could be pursued to further test the utility of the CNB construct 
For example, qualitative research of individuals with BD, stratified by CNB class, may provide 
important new insight into the patients’ perspective of their treatment, relationships with their 
provider, and their perspectives of the benefit versus risks of their treatment. This would lend 
support, or suggest there is limited utility, of the subgroups identified by CNB. In addition, other 
measures of adherence such as pill bottle counts, blood serum levels, and self-report 
questionnaires of adherence (e.g., Medication Adherence Rating Scale) may be more sensitive 
measures than the metric of adherence used here. 
 Additionally, the CNB construct could be tested in different clinical populations, such as 
with individuals diagnosed with schizophrenia (e.g., CATIE Schizophrenia trial) or major 
depression (e.g., STAR*D trial), to understand the heterogeneity in these dimensions across a 
range of psychiatric disorders. These RCTs have similar designs to STEP-BD. If we are able to 
identify distinct subgroups of CNB in these populations, this would further support the utility of 
the CNB construct in understanding heterogeneity in treated populations with psychiatric 
disorders, regardless of whether that heterogeneity predicts adherence. Finally, it would be 
important to explore the construct of CNB in observational, rather than clinical trial, data (e.g., 
population surveys such as the Medical Expenditures Panel Survey), which have superior 
external validity to RCTs. 
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Appendix 
Diagnostic Criteria for Bipolar I Disorder 
For a diagnosis of bipolar I disorder, it is necessary to meet the following criteria for a manic 
episode. The manic episode may have been preceded by and may be followed by hypomanic or 
major depressive episodes. 
 
Manic Episode 
A. A distinct period of abnormally and persistently elevated, expansive, or irritable mood 
and abnormally and persistently increased activity or energy, lasting at least 1 week and 
present most of the day, nearly every day (or any duration if hospitalization is necessary). 
B. During the period of mood disturbance and increased energy or activity, three (or more) 
of the following symptoms (four if the mood is only irritable) are present to a significant 
degree and represent a noticeable change from usual behavior: 
1. Inflated self-esteem or grandiosity. 
2. Decreased need for sleep (e.g., feels rested after only 3 hours of sleep). 
3. More talkative than usual or pressure to keep talking. 
4. Flight of ideas or subjective experience that thoughts are racing. 
5. Distractibility (i.e., attention too easily drawn to unimportant or irrelevant 
external stimuli), as reported or observed. 
6. Increase in goal-directed activity (either socially, at work or school, or 
sexually) or psychomotor agitation (i.e., purposeless non-goal-directed 
activity). 
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7. Excessive involvement in activities that have a high potential for painful 
consequences (e.g., engaging in unrestrained buying sprees, sexual 
indiscretions, or foolish business investments). 
C. The mood disturbance is sufficiently severe to cause marked impairment in social or 
occupational functioning or to necessitate hospitalization to prevent harm to self or 
others, or there are psychotic features. 
D. The episode is not attributable to the physiological effects of a substance (e.g., a drug of 
abuse, a medication, other treatment) or another medical condition. 
o Note: A full manic episode that emerges during antidepressant treatment (e.g., 
medication, electroconvulsive therapy) but persists at a fully syndromal level beyond 
the physiological effect of that treatment is sufficient evidence for a manic episode 
and, therefore, a bipolar I diagnosis. 
Note: Criteria A–D constitute a manic episode. At least one lifetime manic episode is required 
for the diagnosis of bipolar I disorder. 
 
Hypomanic Episode 
A. A distinct period of abnormally and persistently elevated, expansive, or irritable mood 
and abnormally and persistently increased activity or energy, lasting at least 4 
consecutive days and present most of the day, nearly every day. 
B. During the period of mood disturbance and increased energy and activity, three (or more) 
of the following symptoms (four if the mood is only irritable) have persisted, represent a 
noticeable change from usual behavior, and have been present to a significant degree: 
1. Inflated self-esteem or grandiosity. 
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2. Decreased need for sleep (e.g., feels rested after only 3 hours of sleep). 
3. More talkative than usual or pressure to keep talking. 
4. Flight of ideas or subjective experience that thoughts are racing. 
5. Distractibility (i.e., attention too easily drawn to unimportant or irrelevant 
external stimuli), as reported or observed. 
6. Increase in goal-directed activity (either socially, at work or school, or 
sexually) or psychomotor agitation. 
7. Excessive involvement in activities that have a high potential for painful 
consequences (e.g., engaging in unrestrained buying sprees, sexual 
indiscretions, or foolish business investments). 
C. The episode is associated with an unequivocal change in functioning that is 
uncharacteristic of the individual when not symptomatic. 
D. The disturbance in mood and the change in functioning are observable by others. 
E. The episode is not severe enough to cause marked impairment in social or occupational 
functioning or to necessitate hospitalization. If there are psychotic features, the episode 
is, by definition, manic. 
F. The episode is not attributable to the physiological effects of a substance (e.g., a drug of 
abuse, a medication, other treatment) or another medical condition. 
o Note: A full hypomanic episode that emerges during antidepressant treatment (e.g., 
medication, electroconvulsive therapy) but persists at a fully syndromal level beyond 
the physiological effect of that treatment is sufficient evidence for a hypomanic 
episode diagnosis. However, caution is indicated so that one or two symptoms 
(particularly increased irritability, edginess, or agitation following antidepressant use) 
152 
 
are not taken as sufficient for diagnosis of a hypomanic episode, nor necessarily 
indicative of a bipolar diathesis. 
Note: Criteria A–F constitute a hypomanic episode. Hypomanic episodes are common in bipolar 
I disorder but are not required for the diagnosis of bipolar I disorder. 
 
Major Depressive Episode 
A. Five (or more) of the following symptoms have been present during the same 2-week 
period and represent a change from previous functioning; at least one of the symptoms is 
either (1) depressed mood or (2) loss of interest or pleasure. 
o Note: Do not include symptoms that are clearly attributable to another medical 
condition. 
1. Depressed mood most of the day, nearly every day, as indicated by either 
subjective report (e.g., feels sad, empty, or hopeless) or observation made by 
others (e.g., appears tearful). (Note: In children and adolescents, can be 
irritable mood.) 
2. Markedly diminished interest or pleasure in all, or almost all, activities most 
of the day, nearly every day (as indicated by either subjective account or 
observation). 
3. Significant weight loss when not dieting or weight gain (e.g., a change of 
more than 5% of body weight in a month), or decrease or increase in appetite 
nearly every day. (Note: In children, consider failure to make expected weight 
gain.) 
4. Insomnia or hypersomnia nearly every day. 
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5. Psychomotor agitation or retardation nearly every day (observable by others; 
not merely subjective feelings of restlessness or being slowed down). 
6. Fatigue or loss of energy nearly every day. 
7. Feelings of worthlessness or excessive or inappropriate guilt (which may be 
delusional) nearly every day (not merely self-reproach or guilt about being 
sick). 
8. Diminished ability to think or concentrate, or indecisiveness, nearly every day 
(either by subjective account or as observed by others). 
9. Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing 
suicide. 
B. The symptoms cause clinically significant distress or impairment in social, occupational, 
or other important areas of functioning. 
C. The episode is not attributable to the physiological effects of a substance or another 
medical condition. 
Note: Criteria A–C constitute a major depressive episode. Major depressive episodes are 
common in bipolar I disorder but are not required for the diagnosis of bipolar I disorder. 
Note: Responses to a significant loss (e.g., bereavement, financial ruin, losses from a natural 
disaster, a serious medical illness or disability) may include the feelings of intense sadness, 
rumination about the loss, insomnia, poor appetite, and weight loss noted in Criterion A, which 
may resemble a depressive episode. Although such symptoms may be understandable or 
considered appropriate to the loss, the presence of a major depressive episode in addition to the 
normal response to a significant loss should also be carefully considered. This decision 
154 
 
inevitably requires the exercise of clinical judgment based on the individual’s history and the 
cultural norms for the expression of distress in the context of loss. 
In distinguishing grief from a major depressive episode (MDE), it is useful to consider 
that in grief the predominant affect is feelings of emptiness and loss, while in an MDE it is 
persistent depressed mood and the inability to anticipate happiness or pleasure. The dysphoria in 
grief is likely to decrease in intensity over days to weeks and occurs in waves, the so-called 
pangs of grief. These waves tend to be associated with thoughts or reminders of the deceased. 
The depressed mood of an MDE is more persistent and not tied to specific thoughts or 
preoccupations. The pain of grief may be accompanied by positive emotions and humor that are 
uncharacteristic of the pervasive unhappiness and misery characteristic of an MDE. The thought 
content associated with grief generally features a preoccupation with thoughts and memories of 
the deceased, rather than the self-critical or pessimistic ruminations seen in an MDE. In grief, 
self-esteem is generally preserved, whereas in an MDE, feelings of worthlessness and self-
loathing are common. If self-derogatory ideation is present in grief, it typically involves 
perceived failings vis-à-vis the deceased (e.g., not visiting frequently enough, not telling the 
deceased how much he or she was loved). If a bereaved individual thinks about death and dying, 
such thoughts are generally focused on the deceased and possibly about “joining” the deceased, 
whereas in an MDE such thoughts are focused on ending one’s own life because of feeling 
worthless, undeserving of life, or unable to cope with the pain of depression. 
Bipolar I Disorder 
A. Criteria have been met for at least one manic episode (Criteria A–D under “Manic 
Episode” above). 
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B. The occurrence of the manic and major depressive episode(s) is not better explained by 
schizoaffective disorder, schizophrenia, schizophreniform disorder, delusional disorder, 
or other specified or unspecified schizophrenia spectrum and other psychotic disorder. 
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